Graduate Theses, Dissertations, and Problem Reports
2020

Multimorbidity, Immune Checkpoint Inhibitor Use, and Healthcare
Expenditures among Older Patients with Late-stage Melanoma
Pragya Rai
West Virginia University, pr0001@mix.wvu.edu

Follow this and additional works at: https://researchrepository.wvu.edu/etd
Part of the Epidemiology Commons, Health Services Research Commons, Neoplasms Commons,
Pharmacoeconomics and Pharmaceutical Economics Commons, and the Pharmacy Administration,
Policy and Regulation Commons

Recommended Citation
Rai, Pragya, "Multimorbidity, Immune Checkpoint Inhibitor Use, and Healthcare Expenditures among Older
Patients with Late-stage Melanoma" (2020). Graduate Theses, Dissertations, and Problem Reports. 7789.
https://researchrepository.wvu.edu/etd/7789

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

Multimorbidity, Immune Checkpoint Inhibitor Use, and Healthcare Expenditures among Older
Patients with Late-stage Melanoma

Pragya Rai

Dissertation submitted
to the School of Pharmacy
at West Virginia University
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy in
Health Services and Outcomes Research

Usha Sambamoorthi, Ph.D, Chair
Kimberly M. Kelly, Ph.D
Virginia G. Scott, Ph.D, MS, BSPharm
Joanna Kolodney, MD
Chan Shen, Ph.D.

Department of Pharmaceutical Systems and Policy

Morgantown, West Virginia
2020

Keywords: Melanoma, Metastatic melanoma, Multimorbidity, Multiple chronic conditions,
Immune checkpoint inhibitors, Healthcare expenditures, Older patients

Copyright 2020 Pragya Rai

ABSTRACT
Multimorbidity, Immune Checkpoint Inhibitor Use, and Healthcare Expenditures among Older
Patients with Late-stage Melanoma
Pragya Rai
With decades of unchanged cancer care with no added survival benefit, immune checkpoint
inhibitors (ICI) changed the treatment landscape of late-stage melanoma in 2011. A key factor in
determining the use of ICIs is the presence of pre-existing chronic conditions, which can
influence the outcome. However, the prevalence of multimorbidity (defined as presence of two
or more chronic conditions) among older patients with late-stage melanoma remains unknown.
It also remains unknown if the presence of multimorbidity factors into the use of ICIs. Hospitalrelated factors associated with ICI use have been studied. Yet, patient-level factors, such as age,
sex, marital status, which may play a more crucial role in the use of ICIs, remain unknown.
Furthermore, ICI use may exacerbate healthcare expenditures for an already expensive condition,
i.e., late-stage cancer. There are no studies exploring the effects of ICI on healthcare
expenditures among the elderly. Therefore, this study had three main objectives (1) to examine
the prevalence and type of pre-existing multimorbidity and the associated risk factors, (2) to
assess the association of multimorbidity and other risk factors on ICI use, and (3) to assess the
impact of ICI and multimorbidity on healthcare expenditures among older patients with latestage melanoma. Retrospective cohort studies were conducted using Surveillance,
Epidemiology, and End Results cancer registry linked with fee-for-service Medicare claims for
older (>66 years) patients with a 12-month pre-index and 12-month post-index period. Index
date was the date of incident stage III/stage IV melanoma diagnosis between 2011 and 2015.
Logistic regression was used to examine the associations of multimorbidity or ICI use to various
patient-level factors. Generalized linear mixed models with gamma distribution and log-link was
used to analyze adjusted relationships between ICI/multimorbidity and healthcare expenditures.
In the first aim, an overwhelming majority (85%) of older adults with late stage melanoma had
pre-existing multimorbidity. The second aim concluded that only 6% of older adults with latestage melanoma received ICI. Multimorbidity was not significantly associated with ICI use.
Factors positively associated with ICI use were lower age, social support in the form of spouse,
residence in the Northeastern regions, and had dual eligibility compared to their counterparts.
This study concluded that patient-level factors may play a significant role in decisions towards
treatment of late-stage melanoma with ICI, regardless of multimorbidity. The third study
reported that the average total, outpatient, home health, and inpatient healthcare expenditures in
the pre-index period were significantly (p < 0.001) lower than the expenditures in the post-index
period. In addition, regardless of multimorbidity, the high expenditures in post-index period
were influenced by the use of ICI. Therefore, ICI use was significantly associated with
healthcare expenditures. In summary, multimorbidity is a growing concern for oncologists,
especially among the elderly. The high prevalence of multimorbidity among elderly in our study
points to the fact that multimorbidity should be factored into cancer care. Since multimorbidity
is not included in cancer care guidelines, it does not play a role in receipt of ICI among older
patients. However, the use of ICI significantly increases healthcare expenditures. To reduce
costs, newer payment models that focus on value are being developed and tested. Future studies
need to examine whether such models can achieve the triple aims of “better health, better value,
and lower costs.”
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CHAPTER 1
1. BACKGROUND AND SIGNIFICANCE
1.1. Introduction
Melanoma Prevalence and Incidence
Melanoma is a type of skin cancer which arises from uncontrollable proliferation of
melanocytes.1 Historically a rare cancer, its incidence has risen faster than any other cancer.1
This rise in incidence has been primarily attributed to tanning beds, though other risk factors
such as sun exposure and other environmental factors cannot be ruled out.1,2 The incidence rose
from 1 in 1,500 in 1935 to 1 in 30 in 2015.3 In 2020, approximately 100,000 Americans will be
diagnosed with melanoma.4,5 This rise in incidence has made melanoma the fifth most common
cancer in the United States (US).5 If caught early, prognosis of melanoma is favorable.3,6
However, once melanoma has metastasized, treatment becomes difficult with a grim long-term
prognosis; median overall survival rates range from 6 to 8 months.7,8 Further, the 1- and 2-year
survival rates for patients with metastatic melanoma were 23% and 9% respectively.9
Melanoma in the elderly
Globally, the greatest burden of melanoma falls on residents of Australia, Europe, New
Zealand, the elderly and male population.10 The incidence in the older population continues to
rise in the US while the incidence in younger population appears to be leveling off.11 Nearly
50% of all melanoma deaths in the US occur in white men older than 50 years.11 One of the
reasons for higher death rates among the older population (>65 years) is immunosenescense,
which means as we age, our immune system declines.11 Therefore, older patients have reduced
capacity to fight infections and malignancy. Another reason for the high mortality rate among
the elderly is that several poor prognostic factors, including non-superficial spreading histology,
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higher Clark invasion level, lower Breslow thickness, and presence of ulceration, were
significantly observed in the elderly.
In addition, as patients age, the factors of primary melanoma become more advanced and
melanoma is more likely to develop poorer histological features.12 Therefore, older patients are
more likely to be diagnosed with late-stage (Stage III/IV) melanoma.12 A study noted that older
patients had higher primary tumor stage, higher Breslow thickness, ulceration, and poorer
survival compared to younger (18-64 years) patients.12 Therefore, this dissertation will focus on
older patients with late-stage melanoma.
Treatment of late-stage melanoma
Once melanoma has been diagnosed, there are multiple options for treatment. Prior to
2011, management of metastatic melanoma included single-agents (alkylating agents,
microtubule disrupting agents, platinum analogs, and nitrosoureas), as well as combination
chemotherapy along with surgery and radiation therapy.13,14 However, these therapies did not
significantly improve survival and were often associated with high toxicity.14–16 This led to the
advent of immune checkpoint inhibitors (ICI; including ipilimumab, nivolumab, and
pembrolizumab) since 2011, which have significantly improved survival with less toxic side
effects.17,18 A departure from chemotherapy, ICIs work by energizing the immune system of the
body to fight off the cancer cells.17,18 Recent data of 5.3 years median follow-up for ipilimumab,
an anti-CTLA-4 agent, yielded significantly better distant metastasis free survival compared to
standard chemotherapy, with no additional toxicities reported since the initial report at 2.3
years.19,20 Even superior overall survival, progression free survival, objective response rates, and
better safety profile were observed with anti-PD-1/PD-L1 agents (nivolumab and
pembrolizumab).20–22 This led many researchers to explore the efficacy of combination ICI.

2

Early data from ongoing randomized clinical trials (RCTs) have shown durable response with
combination ipilimumab and nivolumab.23 Such promising results from RCTs led to the
integration of ICI (monotherapy or combination) as the first-line treatment for metastatic
melanoma.24,25
Multimorbidity
People often live with two or more chronic conditions. Aging population and increase in
life expectancy means that the number of people living with increasing number of chronic
conditions will continue to rise.26 This “multimorbidity” or the coexistence of two or more
chronic conditions in the same individual will have an impact on their safety in primary and
specialty care. The safety concerns arise due to multiple reasons, including26
•

polypharmacy, which may lead to poor medication adherence and adverse drug events,

•

complex management regimens,

•

more frequent and complex interactions with health care services leading to greater
susceptibility to failures of care delivery and coordination,

•

the need for clear communication and patient-centered care due to complex patient
needs,

•

demanding self-management regimens and competing priorities, and

•

more vulnerability to safety issues due to poor health, advanced age, cognitive
impairment, limited health literacy, and comorbid depression or anxiety.
Therefore, recent years has seen an increase in research on multimorbidity to alleviate the

safety concerns for such individuals.

3

Multimorbidity in the elderly
Studies have shown that prevalence of multimorbidity is on the rise worldwide. A study
conducted in one developed country reported that almost 25% of the entire population has
multimorbidities.26 Recent literature has shown high levels of multimorbidity in low- and
middle-income countries.26 Similar trend has also been observed in high-income countries. For
example, in Sweden, the prevalence of multimorbidity was 56.3% among adults aged 35 to 75
years.27 In the United States (US), one in four adults were reported to have multimorbidity, with
68% of the elderly individuals having two or more chronic conditions and 36% having four or
more chronic conditions.28 Another study reported similar findings among Medicare
beneficiaries: 62% aged 65 to 74 years, 75.7% aged 75 to 84 years, and 81.5% aged 85 years and
above had multimorbidity.29 In addition, female Medicare beneficiaries had higher prevalence of
multimorbidity compared to males.29
Such high prevalence has serious consequences on health outcomes of the elderly.
Studies have shown that multimorbidity is associated with an increased risk of death, disability,
poor functional status, poor quality of life, adverse drug events, and other adverse outcomes.29–31
Despite efforts to reduce multimorbidity among the elderly, the condition remains rampant.
Therefore, studies as this are needed to provide information on the impact of multimorbidity on
newly diagnosed conditions, such as cancer.
Late-stage melanoma and multimorbidity
Prevalence of multimorbidity among older patients with late-stage melanoma
The prognosis, treatment, and health outcomes (including survival) of patients with latestage melanoma depends on a number of factors, including age, tumor characteristics, and
presence or absence of comorbidities.29,32 The presence of comorbidities influence cancer
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detection, treatment, and progression of cancer. This in turn can affect the prognosis and longterm survival of the patients. Patients with comorbidities are at higher risk of complications and
lower performance status, may have decreased quality of life, and may face more life-threating
conditions. Despite the importance of considering comorbidities in treatment and prognosis of
melanoma, the prevalence of comorbidities has received little attention.
There are few studies on the impact of comorbidities of melanoma stage of diagnosis,
treatment, and health outcomes. These studies reported that the prevalence of chronic conditions
varies from 19% to 80% among adult patients with malignant melanoma.25,33–36 These studies
did not focus on late-stage melanoma because of poor survival among those patients. However,
the advent of ICIs may result in an increase in late-stage melanoma survivors. Therefore,
identifying prevalent conditions in patients with late-stage melanoma will allow healthcare
professionals to tailor their long-term care for each individual.
Moreover, the studies do not usually include mental health conditions. Literature also
suggests that those with mental health conditions may have barriers to cancer care.37 However,
most studies on patients with cancer have focused only on anxiety and depression; the presence
of other mental health conditions, such as dementia, can also lead to less-aggressive cancer
treatment because of compromised informed consent and adverse effects.38–41 Therefore,
estimating the prevalence of any type of multimorbidity can be useful to the providers as well as
patients.
In addition, one of the conditions worrisome for oncologists is autoimmune disease. This
is because ICI therapy can induce autoimmune side effects affecting almost any organ system,
specifically aberrant activation of immune cells against self-antigens, referred to as “immunerelated adverse events (irAE)”.42 Patients with pre-existing autoimmune diseases may be at a
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greater risk for developing irAEs.43 Therefore, these patients were largely excluded from RCTs
of ICI. However, a recent study reported that the prevalence of autoimmune diseases has been
increasing from 17.1% in 2004 to 28.3% in 2014.36 Although autoimmune diseases are more
frequent in the older patients, occurrence of autoimmune disease multimorbidity remains
unknown. Therefore, a study which included a comprehensive list of mental health conditions
and autoimmune diseases is necessary because studies often include only limited mental health
conditions and no autoimmune diseases. In addition, examining factors (i.e., risk profile) other
than age that may be associated with multimorbidity can help in assessing disease burden,
surveillance, treatment decisions, and survivorship plans of patients with late-stage melanoma,
justifying rationale for Aim 1.
Factors associated with ICI use among older patients with late-stage melanoma
Since the approval of ICI in 2011, literature on the improved survival associated with
ICIs have increased exponentially. It stands to reason that the use of ICI in real-world setting
may be commonplace. However, that is not the case; adoption of ICIs has been slow. We
speculate few reasons for this slower diffusion of innovation. First, with their strict inclusion
and exclusion criteria, RCTs of ICIs did not provide robust evidence on the use and impact of
ICI among the elderly. Additionally, multimorbidity is prevalent among the older patients.
Layering the management of melanoma onto the management of a patient with multimorbidity
further compounds the complexity of care. The interplay between treatment approaches used for
melanoma care and those used for multimorbidity can be complicated. In patients with preexisting multimorbidity, a new diagnosis of cancer adds a new dynamic, with the primary care
physicians and other specialists shifting into supportive roles, to deliver non-cancer care in the
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context of cancer treatment.44,45 With lack of evidence from RCTs, decision-making on
choosing ICI treatment for care may become difficult.
In addition, certain patient-level factors may be considered as a source of slower adoption
of newer therapies. Studies on other cancers have shown some subgroups may be less likely to
receive treatment. For example, age and racial disparities on treatment received was reported
among older patients with late-stage pancreatic adenocarcinoma.46 Patients below the age of 80
years and White non-Hispanics were more likely to receive treatment than those above 80 years
of age and other race/ethnicity.46 Similarly, a study among older patients with bladder cancer
reported better survival among married patients than unmarried ones, because of greater
likelihood of receiving treatment.47 Financial aspects potentially affecting the care setting for
late-stage melanoma patients may also be a potential reason.48 Insured patients are more likely
to receive ICIs compared to uninsured or underinsured patients.49 With evident disparities in
receipt of treatment, it is critical to know whether some subgroups lag in the diffusion of
innovative therapies like ICIs, so that oncologists and patients alike can make informed
decisions when considering ICIs as the treatment option, thus justifying rationale for Aim 2.
Healthcare expenditure associated with ICI among older patients with multimorbidity and
late-stage melanoma
The economic burden associated with cancer is substantial. There is robust evidence that
cancer increases healthcare expenditures. The costs differ by type and stage of cancer.
Therefore, although the cost of malignant melanoma is the lowest compared to other cancers,
metastasis of melanoma significantly increases healthcare expenditures. 50–52 In fact, 55% of the
annual direct cost for treating melanoma arose from late-stage melanoma and one-third of the
total cost was related to the end-of life melanoma treatment.53 The annual treatment costs ranged
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from $44.9 million among Medicare patients with existing melanoma to $932.5 million among
newly diagnosed cases across all groups.54 Among Medicare beneficiaries, the average perpatient melanoma charges were $2,194 during the initial four months of treatment and increased
to $3,933 during the terminal six months of treatment in 2010.55
Such costs are bound to increase with time due to inflation. However, recent years has
seen a substantial increase in cancer-related healthcare costs. The high healthcare expenditures
for late-stage melanoma may be driven by many factors such as high cost of ICIs, the associated
administration costs for these drugs, and supporting care (monitoring and testing).56 One of the
concerns are the high costs of ICIs. According to Dr. Leonard Saltz, the costs of newer therapies
“approximately 4,000 times the cost of gold”.57 He calculated that the cost for a typical patient
receiving the CheckMate067 combination (ipilimumab and nivolumab) would have been
$295,566.57 With a 20% co-pay, the out-of-pocket cost to the patients would have totaled
$60,000. In addition, serum biomarker testing and enzyme level monitoring are common before
and during treatment of late-stage melanoma.58 These functions also factor into the cost of
melanoma care. Therefore, this amounted to $174 billion for treating late-stage melanoma for
one year only.57
Further, the presence of multimorbidity may further exacerbate the costs. Healthcare
resource utilization is high among patients with multimorbidity, with frequent visits to specialists
and higher hospitalization rates. Therefore, there was a positive associated between
multimorbidity and healthcare costs, with an average increase of $1,774 in total costs for each
body system affected by chronic conditions.59 It is reasonable that older adults with
multimorbidity treated with ICIs will therefore incur the highest healthcare expenditures.
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It should be kept in mind that almost no patients pay for their treatments. Rather, the
society collectively pay the price for the expensive therapies. When an individual gets a
treatment, others pay through insurance premiums and/or taxes that support Medicare, Medicaid,
or other government programs. Therefore, when medical costs increase, so do the insurance
premiums. These rising premiums may in turn harm the very people who need it the most, by
reducing their access to care because they may be unable to purchase coverage. Examining the
healthcare expenditures and the reason behind the increase will allow various stakeholdershealthcare professionals, payers, organization- to identify and condemn practices with
unreasonable costs, thus justifying the rationale for Aim 3.
1.2. Innovation
a) Comprehensive evaluation of chronic conditions among older patients with latestage melanoma: This is the first study to include a comprehensive list of physical and mental
health conditions when evaluating the prevalence of multimorbidity. In addition, the updated list
includes the autoimmune diseases based on the current challenges with ICI use.
b) Novel factors of ICI adoption: Studies have evaluated the role of healthcare
practices in adopting ICIs. However, patient-level factors have not been evaluated. As shared
decision-making is common practice, patient-level factors that influence the adoption of newer
therapies might provide oncologists with leads to make headway on improving uptake of ICIs.
c) Fill a significant knowledge gap in literature: Given that no studies have examined
multimorbidity among older patients with late-stage melanoma, the proposed study will fill an
important knowledge gap in the literature by identifying the prevalence of various chronic
conditions in such patients.
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1.3. Specific Aims
Aim 1.1: Estimate the prevalence and type of multimorbidity prior to the diagnosis
of late-stage melanoma
Aim 1.2: Evaluate the association of patient-level factors to multimorbidity in older
patients with late-stage melanoma
Hypothesis 1.2: In the fully adjusted model which will include all the independent
variables, age will be significantly associated with multimorbidity among older patients with
late-stage melanoma.
Aim 2: Examine the association of multimorbidity and other factors to ICI use that
cover years from the initial introduction in 2011 to 2015 among older patients with latestage melanoma
Hypothesis 2: In the fully adjusted model, year of diagnosis, age, marital status, dual
eligibility, and region of residence will be significantly associated with ICI use among older
patients with late-stage melanoma.
Aim 3.1: Estimate the impact of ICI use on healthcare expenditures during pre- and
post-late-stage melanoma diagnosis periods among older patients with late-stage melanoma
Hypothesis 3.1: ICI use will be associated with high expenditures throughout the
treatment period compared to those without ICI use.
Aim 3.2: Estimate the impact of ICI-multimorbidity interaction on healthcare
expenditures during pre- and post-late-stage melanoma diagnosis periods among older
patients with late-stage melanoma
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Hypothesis 3.2: Patients who used ICI and had multimorbidity will have higher
expenditures throughout the treatment period compared to ICI non-users and those without
multimorbidity.
1.4. Approach
Conceptual Frameworks Used to Guide the Selection of Variables
A conceptual framework was created by adapting determinants of health outcomes and
chronic disease model and Andersen’s healthcare utilization model.60,61 According to these
models, outcomes
such as presence of
multimorbidity,
receipt of novel
therapies (ICI), and
consequently
healthcare
Figure 1.1: Adapted
determinants of health outcomes
and chronic disease model and
Andersen’s healthcare
utilization model

expenditures are based
on the presence or
absence of multiple

factors. These factors included biological factors, social factors, community resources, socioeconomic status, and year of diagnosis. Biological factors consisted of age (66-69, 70-74, 75-79,
and ≥80 years), sex (male/female), and race (white/non-White). Social factors included marital
status (married/not married). Community resources included regions (Northeast, South, West,
and Northcentral). Dual Medicare/Medicaid enrollment (yes/no) was a proxy for low economic
status. Years of incident melanoma diagnosis (2012-2015) was used to control for changes in
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practice patterns. Aim 3 also included healthcare utilization (visits to primary care physician and
oncologists).
Data sources
Data from multiple sources were used to accomplish the study aims.
Surveillance, Epidemiology, and End Results (SEER): SEER is a cancer registry and
provides data on clinical variables related to cancer. SEER data consists of various files, which
contain information on patients and cancers. Patient Entitlement and Diagnosis Summary File
provides information for each person’s date of birth, sex, race, and state of residence. This file
also includes information on Medicare eligibility, reason for Medicare entitlement, and health
maintenance organization (HMO) enrollment by month. In addition, these files also contain
geographically-based (ZIP code and census tract level) socioeconomic information. The file
contains exhaustive information on cancer, such as diagnosis date, cancer stage, tumor size,
number of positive lymph nodes, and tumor histology.
SEER-Medicare Claims: Medicare Enrollment File: Medicare is the federally funded
program that provides health insurance to the elderly, persons with end-stage renal disease, and
some disabled. For persons aged 65 and over, nearly 90% are Medicare eligible. Medicare
claims provides information on Part A coverage (hospital, skilled nursing facility, hospice and
some home healthcare), Part B coverage (physician and outpatient services), Part C (HMO
enrollment, most of whom have fee-for-service coverage), and Part D (prescription drug)
coverage. Medicare claims database is the best source of information to estimate Medicare
payments among the elderly for cancer and other disease states. To link SEER with Medicare
data, identifiers contained in the Medicare’s master enrollment file is matched with individual
identifiers for all persons in their files.
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American Community Survey (ACS) Census Tract Files: The ACS census tract and
census zip code files were linked to PEDSF files by geographic codes, such as, state and county.
These files provided information on the census tract median household income and education
level.
Area Health Resource File (AHRF): The AHRF is a publicly available data file
provided by Department of Health and Human Services and contains county, state and national
files. The AHRF provides more than 6,000 variables for each of the nation's counties. The AHRF
contains information such as health facilities, health professions, and socioeconomic and
environmental characteristics. The basic file contains geographic codes and descriptors that may
be used to link it to other files and to aggregate counties into various geographic groupings. This
study used the AHRF variables to measure health care infrastructure that can influence the
detection of multimorbidity, ICI use and expenditures.
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CHAPTER 2
2. PREVALENCE AND RISK FACTORS FOR MULTIMORBIDITY IN ELDERLY US
PATIENTS WITH LATE-STAGE MELANOMA
2.1. Abstract
Introduction: Presence of multimorbidity can affect prognosis, treatment, and outcomes
of individuals with cancer. However, the prevalence and factors associated with multimorbidity
among older late-stage melanoma is not well studied. We estimated the prevalence of any type of
pre-existing multimorbidity (autoimmune disorder (AD), physical health conditions (PHC), and
mental health conditions (MHC)) among older adults with late-stage melanoma in the United
States. We further examined the association of patient-level factors to multimorbidity in latestage melanoma.
Methods: We derived data on older fee-for-service Medicare beneficiaries (age ≥66
years) diagnosed with late-stage melanoma between 2011 and 2015 (N = 4,519) from the linked
Surveillance, Epidemiology, and End Results cancer registry and Medicare claims. We defined
multimorbidity as the prevalence of two or more chronic conditions prior to the diagnosis of
melanoma. We used unadjusted and adjusted logistic regressions to examine the association of
patient-level factors to multimorbidity.
Results: An overwhelming majority (85%) of older patients with late-stage melanoma
had multimorbidity. Pre-existing PHC multimorbidity (84%) was the most prevalent, followed
by AD (12%), and MHC (6%). Age and region were associated with any and PHC
multimorbidity. Sex, marital status, and region were factors associated with pre-existing AD
while sex, marital status, and dual eligibility were associated with MHC multimorbidity.
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Conclusions: Pre-existing multimorbidity was highly prevalent among older individuals
with late-stage melanoma; prevalence rates and factors associated with multimorbidity varied by
type of chronic conditions. This highlights the need for developing systematic approaches to
optimizing care of older patients with late-stage melanoma and multimorbidity.
2.2. Introduction
Melanoma is a form of skin cancer with an alarmingly-rising incidence in the United
States (US), making it the fifth most common cancer, with the highest occurrence among the
elderly (≥65 years).2,62,63 Although melanoma accounts for 2% of all skin cancers, late-stage
melanoma is the most lethal, accounting for 90% of deaths.2 A key factor for treatment of
patients with melanoma is having a pre-existing chronic condition. Pre-existing chronic
conditions are highly prevalent in all cancers and have been shown to affect cancer stage at
diagnosis, treatment, and outcomes; melanoma being no exception.32,64 The prevalence of
chronic conditions in patients with melanoma varies from 19% to 80%.33,34 The presence of
additional chronic conditions prevents physicians from aggressively treating melanoma, thereby
increasing the risk of mortality.33,34
As patients age, the number of chronic conditions increases.29 Some studies focused on
the presence of multimorbidity, defined as the presence of two or more chronic conditions,
among patients with breast, bladder, and colorectal cancers.65–68 These studies also documented
high prevalence of multimorbidity and associated adverse outcomes. However, to date no study
has exclusively examined multimorbidity in patients with late-stage melanoma perhaps due to
the poor survival of these patients. Studies of multimorbidity among late-stage melanoma
patients are important and needed for reasons stated below.
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Immune checkpoint inhibitors (ICI) have changed the treatment landscape of late-stage
melanoma, with significant improvements in survival.6,69 However, pre-existing multimorbidity
may compete with cancer care because cancer treatment needs to focus not only on mortality but
also treatment complications and quality of life.70 For example, ICIs affect the immune
system.18 Patients with pre-existing autoimmune diseases (AD) have weaker immune systems,
and this may deter their treatment with ICI, due to fears of higher mortality and worse quality of
life post-treatment.42,71 As ICIs are often used in cancer patients with pre-existing AD seeking
care in the real-world settings,42,43,72 it is critical to assess the prevalence of pre-existing AD in
the elderly. Furthermore, literature also suggests that those with mental health conditions
(MHCs) may have barriers to cancer care.37 However, most studies on patients with cancer have
focused only on anxiety and depression; the presence of other MHCs, such as dementia, can also
lead to less-aggressive cancer treatment because of compromised informed consent and adverse
effects.38–41 Therefore, estimating the prevalence of any type of multimorbidity can be useful to
the providers as well as patients. Including a comprehensive list of MHCs and ADs is necessary
because studies often include only limited MHCs and no ADs. In addition, examining factors
(i.e. risk profile) other than age that may be associated with multimorbidity can help in assessing
disease burden, surveillance, treatment decisions, and survivorship plans of patients with latestage melanoma.
Therefore, the objectives of the current study are to estimate the prevalence and type of
multimorbidity prior to the diagnosis of late-stage melanoma and assess the association of
patient-level factors to multimorbidity in older patients with late-stage melanoma.
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2.3. Methods
Study Design
We adopted a retrospective cohort design. The cohort consisted of older adults with
incident late-stage (stage III/IV) melanoma diagnosis based on the American Joint Committee on
Cancer 7th Edition. Index date was defined as the date of incident late-stage melanoma
diagnosis. Pre-index period was defined as 12 months before incident melanoma diagnosis.
Multimorbidity, type of multimorbidity, and all independent variables were assessed during the
pre-index period. The study was exempted by West Virginia University Institutional Review
Board.
Data Source
Surveillance, Epidemiology, and End Results (SEER) cancer registry and Medicare
claims files were used. The SEER data provided information on clinical variables related to
cancer (example: stage of cancer at diagnosis); Medicare claims provided information on
healthcare encounters of the beneficiaries when enrolled and using Medicare covered health
services.
Study Population
We identified 41,848 individuals with incident melanoma diagnosis between 2011 and
2015 using ICD-O-3 site (C44.0 - C44.9) and histology (8720 – 8790) codes. Following the
exclusion of those with local or regional (stage I/II) melanoma, non-incident melanoma, below
the age of 66 years, not continuously enrolled in Medicare part A and Part B during the pre-index
period, and diagnosed with late-stage cancer during autopsy, the final analytical cohort
comprised 4,519 individuals with late-stage melanoma.
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Measures
Dependent variables: Any, PHC, MHC, and AD multimorbidity
Multimorbidity was defined as the presence of ≥2 chronic conditions prior to the
diagnosis of incident late-stage melanoma. We used the list of chronic conditions developed by
the Multiple Chronic Conditions working group within the US Department of Health and Human
Services Office of Assistant Secretary of Health.73 The list was developed based on the
conditions that met the definition of chronicity, are prevalent, and are potentially amenable to
public health. Based on the current challenges with ICIs, pre-existing AD was added, which
were identified from a list of 131 conditions provided by the American Autoimmune-Related
Disease Association (Appendix 7.1).74 All these conditions were identified with International
Classification of Diseases (ICD), 9th Edition.
Physical Health Conditions (PHC) consisted of pre-existing AD, arthritis, asthma,
coronary artery disease, cardiac arrhythmias, diabetes, congestive heart failure, chronic kidney
disease, chronic obstructive pulmonary disease (COPD), hepatitis, hyperlipidemia, hypertension,
human immunodeficiency virus, obesity, osteoporosis, and stroke.
To explore the PHC most prevalent among those with multimorbidity, we created a
taxonomy of PHC. The groups were: cardiovascular diseases (CVD - coronary artery disease,
cardiac arrhythmias, congestive heart failure, and hypertension), endocrine diseases (diabetes,
hyperlipidemia, and obesity), musculoskeletal diseases (arthritis, osteoporosis, and pre-existing
AD), and respiratory diseases (asthma and COPD).
Mental health conditions (MHC) consisted of anxiety, bipolar disorder, depression,
psychoses, schizophrenia, and substance abuse.
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We also added PHC groups (CVD, endocrine, musculoskeletal, and respiratory diseases)
and MHCs to explore any multimorbidity using combinations of dyads (e.g. CVD /endocrine
diseases, MHC/respiratory diseases) and triads (e.g. CVD/endocrine diseases/MHC).
Indices of pre-existing conditions for each of the categories (PHC, MHC, and AD) were
also created. These were derived by counting the number of conditions in each of the groups;
PHC index ranged from 0-13, MHC index from 0-5, and AD index from 0-6.
Independent variables
These were identified at the pre-index period and included biological and social factors,
community resources, socio-economic status, and year of diagnosis. Biological factors consisted
of age (66-69, 70-74, 75-79, and ≥80 years), sex (male/female), and race (white/non-white).
Social factors included marital status (married/not married). Community resources included
regions (Northeast, South, West, and Northcentral). Dual Medicare/Medicaid enrollment
(yes/no) was used as a proxy for low economic status. Years of incident melanoma diagnosis
(2012-2015) was used to control for changes in practice patterns.
Statistics
Chi-square tests were used to identify significant unadjusted associations of individual
characteristics to multimorbidity. Multivariable logistic regressions were performed to determine
the factors associated with multimorbidity. Parameter estimates are presented as adjusted odds
ratios (AORs) after adjusting for all independent variables, with their corresponding 95%
confidence intervals (CI); p ≤ 0.05 was considered statistically significant. All analyses were
conducted using SAS 9.4 (SAS Institute Inc.).
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2.4. Results
The study population was predominantly male (64.2%), White (96.1%) and ≥70 years
(70.4%). The mean number of chronic conditions (including PHCs, MHCs and ADs) was 4.26
with median of 4.0. The mean number of PHCs was 3.98 with median of 4.0. The prevalence of
any PHC was 92.3%; MHC was 20.8% and AD was 28.7%. The most prevalent pre-existing
condition was CVD (78%) followed by endocrine diseases (72%).
Multimorbidity patterns
Multimorbidity was highly prevalent (85%) in the US elderly with late-stage melanoma.
The prevalence of multimorbidity varied by type of chronic conditions: 84% had PHC
multimorbidity, 12% had AD multimorbidity, and 6% had MHC multimorbidity.
Among those with any multimorbidity, the most prevalent dyad combination was
endocrine and musculoskeletal diseases combination (21.7%) followed by CVD and endocrine
disease combination (20.3%). Among triads, CVD, endocrine, and musculoskeletal disease
combination (22.6%) was the most prevalent followed by endocrine, MHC, and musculoskeletal
disease combination (7%).
Factors associated with any multimorbidity
In unadjusted analyses, characteristics of individuals with and without multimorbidity
differed by age and region (Table 2.1). A significantly higher proportion of Medicare
beneficiaries aged ≥80 years had multimorbidity compared to those in the age group 65-69 years
(89.4% versus 77.1%, p < .0001). Multivariable logistic regression on any multimorbidity
showed similar results (Table 2.1). Older adults in the age group 70-74 years (AOR, 1.41;
95%CI, 1.12, 1.76), 75-79 years (AOR, 1.84; 95%CI, 1.44, 2.35) and ≥80 years (AOR, 2.55;
95%CI, 2.04, 3.18) were more likely to have pre-existing multimorbidity compared to those in
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the age group 65-69 years. Older adults residing in the Northcentral (AOR, 0.69; 95%CI, 0.49,
0.96) and Western (AOR, 0.65; 95%CI, 0.51, 0.83) SEER regions were less likely to have any
multimorbidity compared to residents in the Northeastern parts.
Factors associated with PHC multimorbidity
In unadjusted analyses, characteristics of individuals with and without PHC
multimorbidity differed by age and region (Table 2.2). Individuals with PHC multimorbidity
had significantly higher proportion of those aged ≥70 years and residing in Northeastern regions
compared to those without PHC multimorbidity. Multivariable logistic regression on PHC
multimorbidity showed similar results (Table 2.3). Older adults in the age group 70-74 years
(AOR, 1.42; 95%CI, 1.13, 1.77), 75-79 years (AOR, 1.81; 95%CI, 1.42, 2.30) and ≥80 years
(AOR, 2.47; 95%CI, 1.99, 3.06) were more likely to have pre-existing multimorbidity compared
to those in the age group 65-69 years. Older adults residing in the Northcentral (AOR, 0.65;
95%CI, 0.47, 0.90) and Western (AOR, 0.67; 95%CI, 0.53, 0.85) SEER regions of the US were
less likely to have PHC multimorbidity compared to residents in the Northeastern region.
Factors associated with AD multimorbidity
In unadjusted analyses, characteristics of individuals with and without AD
multimorbidity differed by sex and region (Table 2.2). A significantly higher proportion of
females and residing in Northcentral SEER regions compared had AD multimorbidity compared
to men and those residing in Northeastern regions. Multivariable logistic regression on AD
multimorbidity (Table 2.3) confirmed unadjusted associations; females (AOR, 1.81; 95%CI,
1.48, 2.22) were nearly two times as likely to have AD multimorbidity compared to older males.
Unmarried older adults (AOR, 0.79; 95%CI, 0.65, 0.97) and those residing in southern SEER
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regions (AOR, 0.58; 95%CI, 0.42, 0.80) were less likely to have AD multimorbidity compared to
married elderly and residents in the Northeastern regions.
Factors associated with MHC multimorbidity
In unadjusted analyses, characteristics of individuals with and without MHC
multimorbidity differed by sex, marital status, and dual eligibility (Table 2.2). Elderly with
MHC multimorbidity had significantly higher proportion of females, unmarried, and lower
income status. Multivariable logistic regression on MHC multimorbidity showed similar results
(Table 2.3). Older females (AOR, 1.88; 95%CI, 1.46, 2.44) and those not married (AOR, 1.85;
95%CI, 1.41, 2.44) were more likely to have MHC multimorbidity compared to older males and
those married. Older adults with lower income status (AOR, 3.33; 95%CI, 2.14, 5.19) were three
times more likely to have MHC multimorbidity compared to those with higher income status.
2.5. Discussion
There is sparse information on prevalence of multimorbidity among individuals with
melanoma, with no studies focusing on the elderly with late-stage melanoma. This is the first
study to explore the prevalence and factors associated with the presence and type of
multimorbidity among older adults with late-stage melanoma in the US. We found that 4 in 5
older adults with late-stage melanoma had pre-existing multimorbidity. Our estimates are higher
than those found in non-US studies. For example, a Danish study reported multimorbidity in 9%
of patients with melanoma.33 This study included adults (>18 years) and all stages of melanoma.
In contrast, a German study reported multimorbidity in 57% of patients with melanoma. The
difference in estimated prevalence rates among these studies may be due to the differences in the
study population (all stages as opposed to late-stage and older adults as opposed to adults 18
years or older) and time-period (pre-existing versus co-existing conditions).
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The most common comorbid conditions in our study were CVD, endocrine, and
musculoskeletal diseases or a combination of the three in dyads and triads. This is not surprising
given that CVD, endocrine, and musculoskeletal diseases are highly prevalent in older adults.75,76
These diseases and cancer share modifiable risk factors, with some studies stating a bidirectional
relationship between them.77–79 As heart disease, diabetes, and malignant cancers are among the
top five leading causes of age-adjusted mortality,80 healthcare providers managing patients with
late-stage melanoma may need to routinely monitor for the presence of these conditions and
coordinate their care with the primary care physicians.
Among risk factors for any multimorbidity, age is well-established, with studies reporting
that the number of chronic conditions increases with age,29,33 a trend noted in our study as well.
Increasing number of chronic conditions led to late-stage cancer detection, as both the patient
and the physician were distracted by the pre-existing conditions.81 Adding increasing age to the
mix resulted in less aggressive treatment and a dismal chance of entering a clinical trial, as
physicians had to grapple with physical frailty and polypharmacy as well in these patients.33,81
Therefore, oncologists should optimize the treatment of aging patients with multimorbidity to
improve their outcomes.
Regions, namely Northcentral and Western SEER regions, were associated with lower
odds of having multimorbidity. There are no exhaustive studies on SEER geographical
disparities in late-stage melanoma cancer patients, and further research is needed to explain these
results.
Our study also examined type of multimorbidity in terms of PHC, AD, and MHC. Risk
factors for PHC multimorbidity were similar to any multimorbidity, perhaps because PHC was
more prevalent than MHC, making up the bulk of multimorbidity index. Among the PHC, we
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further explored the prevalence of pre-existing AD among older patients. In 2014, the
prevalence of pre-existing AD among individuals with metastatic melanoma was 20%.36,82 Our
study echoed those findings among the elderly as well. Similar to a previous study on patients
with metastatic melanoma and AD, our study also notes sex and region as a risk factor for AD
multimorbidity.36 In addition, this study also notes the presence of social support in the form of
spouses as a risk factor for AD multimorbidity. Spouses are an important source of social
support for patients with any chronic condition.83 Therefore, patients with multiple AD are more
dependent on that social support to manage their conditions.83 Oncologists should consider these
risk factors when deciding if a drug acting via the immune system is the best course of treatment
for older patients.
Consistent with other studies, we observed 30% of older adults with late-stage melanoma
were diagnosed with any MHC.84,85 Similar levels of MHC were also found in individuals with
late-stage breast,38 colorectal,39 and prostate cancer.40 Sex as a risk factor was also observed
with MHC multimorbidity, perhaps because MHC are more prevalent in females compared to
males.86,87 In addition, lack of social support was a risk factor for MHC multimorbidity. Social
deprivation is a known risk factor for MHC among patients with cancer.88,89 We also observed
that dual eligibility was a risk factor for having MHC multimorbidity. Individuals with
melanoma having Medicaid had worse prognosis compared to uninsured and non-Medicaid
individuals, pointing to the importance of socioeconomic status in melanoma care.90 These risk
factors should be assessed in order to reduce further psychological distress and devise
appropriate follow-up interventions.
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2.6. Strengths and limitations
The present study has several limitations. First, SEER does not contain information on
individual behavior such as smoking status, alcohol consumption, or functional status, all of
which can further affect the risk of having multimorbidity. Second, we did not have access to
individual-level socioeconomic factors, such as education and income. Third, we could not
determine the severity of the conditions. Despite these limitations, this study has several
strengths. Although few studies on comorbid conditions in individuals with melanoma exist,
they did not focus on late-stage melanoma, perhaps because the prognosis was poor with low
chances of survival.91 Therefore, prognostic burden of multimorbidity in such individuals was
deemed less important.91 However, newer therapies such as ICIs will improve survivorship of
patients with late-stage melanoma. Therefore, information on the prevalence and type of
multimorbidity in such individuals can help both physicians and patients in choice of cancer
treatment, survivorship plans, and quality of life care. We included an exhaustive list of PHC
and MHC, including pre-existing AD.
2.7. Conclusions
Nearly 4 in 5 older adults with late-stage melanoma had any multimorbidity. The
prevalence of multimorbidity varied by type of conditions with lowest in MHC and highest in
PHC. One in 10 older adults with late-stage melanoma had AD multimorbidity, suggesting
challenges to the management and decisions for treatment. Cardiovascular, endocrine, and
musculoskeletal diseases were the most commonly occurring comorbid conditions, which share
risk factors with cancer. While the risk factors for any multimorbidity were age and region, they
varied depending on the type of multimorbidity. Therefore, surveillance of type of
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multimorbidity in clinical care should routinely be conducted to properly decide the treatment
and follow-up care among older patients with late-stage melanoma.
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Table 2.1
Percent with Immune Checkpoint Inhibitor (ICI) use by Selected Patient-level
Characteristics among Older Adults (age >65 years) with Incident Late-stage
Melanoma during 2012 and 2015
Linked Surveillance, Epidemiology, and End Results and Medicare Claims Database
ICI
No ICI
Variables
N (%)
N (%)
p-value
Significance
ALL
252 (5.6)
4,267 (94.4)
Multimorbidity
Yes
211 (5.5)
3,622 (94.5)
0.62
No
41 (6.0)
645 (94.0)
Year of diagnosis
2012
35 (3.2)
1,060 (96.8)
0.0008
***
2013
63 (5.8)
1,026 (94.2)
2014
74 (6.4)
1,090 (93.6)
2015
80 (6.8)
1,091 (93.2)
Age
66 to 69 years
62 (6.8)
851 (93.2)
0.0004
***
70 to 74 years
76 (7.6)
929 (92.4)
75 to 79 years
45 (5.0)
860 (95.0)
≥80 years
69 (4.1)
1,627 (95.9)
Sex
Female
72 (4.5)
1,545 (95.5)
0.014
*
Male
180 (6.2)
2,722 (93.8)
Race
Whites
239 (5.5)
4,103 (94.5)
0.29
Non-Whites
13 (7.3)
164 (92.7)
Marital Status
Married
163 (7.3)
2,057 (92.7) <0.0001
***
Not married
89 (3.9)
2,210 (96.1)
Dual Medicare/Medicaid eligibility
Yes
17 (10.0)
153 (90.0)
0.0104
*
No
235 (5.4)
4,114 (94.6)
Regions
Northeast
64 (7.9)
748 (92.1)
0.0186
*
South
49 (5.1)
916 (94.9)
North Central
24 (5.1)
451 (94.9)
West
115 (5.1)
2,152 (94.9)
Note: Based on 4,519 older adults with incident late-stage (Stage III/IV) melanoma
continuously enrolled in Medicare Part A & B fee-for service programs 12 months prior
to incident cancer diagnosis. *0.05< p ≤ 0.01; **0.01 < p ≤0.001; *** p< 0.001
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Table 2.2
Percent with Type of Multimorbidity by Selected Patient-level Characteristics
Older Adults (age ≥65 years) with Incident Late-stage Melanoma during 2011 and 2015
Linked Surveillance, Epidemiology, and End Results and Medicare Claims Database
PHC Multimorbidity

AD Multimorbidity

MHC Multimorbidity

% Yes

% No

% Yes

% No

% Yes

% No

2012

83.7

16.3

10.4

89.6

5.0

95.0

2013

82.8

17.2

9.6

90.4

5.1

94.9

2014

85.8

14.2

9.1

90.9

6.4

93.6

2015

83.0

17.0

10.7

89.3

6.9

93.1

65 to 69 years

76.0

24.0

8.8

91.2

6.6

93.4

70 to 74 years

81.9

18.1

9.6

90.4

5.8

94.2

75 to 79 years

85.2

14.8

9.8

90.2

6.0

94.0

≥80 years

88.6

11.4

10.9

89.1

5.5

94.5

Female

84.2

15.8

13.2

86.8

8.8

91.2

Male

83.7

16.3

8.1

91.9

4.2

95.8

White

83.9

16.1

10.1

89.9

5.9

94.1

Non-Whites

83.1

16.9

6.8

93.2

5.6

94.4

Married

84.2

15.8

10.4

89.6

3.9

96.1

Not married

83.6

16.4

9.5

90.5

7.8

92.2

Northeast

87.4

12.6

11.9

88.1

6.3

93.7

South

85.7

14.3

7.2

92.8

6.0

94.0

North central

82.5

17.5

13.5

86.5

8.0

92.0

West

82.1

17.9

9.7

90.3

5.2

94.8

Year of diagnosis

Agea

Sexb,c

Race

Marital statusc

Regiona,b

Dual Medicare/Medicaid Enrollment c
Yes

86.5

13.5

9.4

90.6

17.1

82.9

No

83.8

16.2

10.0

90.0

5.4

94.6

Note: Based on 4,519 older adults with incident late-stage (Stage III/IV) melanoma, continuously enrolled in
Medicare Parts A and B fee-for service programs 12 months prior to incident cancer diagnosis.
AD: Autoimmune diseases; MHC: Mental health conditions; PHC: Physical health conditions
a

represents significant group differences in presence or absence of PHC multimorbidity; b represents significant
group differences in presence or absence of AD multimorbidity; c represents significant group differences in
presence or absence of MHC multimorbidity based on chi-square tests.
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Table 2.3
Adjusted Odds Ratios (AOR) and 95% Confidence Intervals (CI) from
Separate Multivariable Logistic Regressions on Type of Multimorbidity
Older Adults (age ≥65 years) with Incident Late-stage Melanoma during 2011 and 2015
Linked Surveillance, Epidemiology, and End Results and Medicare Claims Database
PHC Multimorbidity

AD Multimorbidity
Prob

AOR

95% CI

[ 0.80 , 1.26]

0.95

0.95

[ 0.76 , 1.19]

1.21

[ 0.96 , 1.52]

MHC Multimorbidity

AOR

95% CI

Prob

AOR

95% CI

2012

1.00

[ 0.73 , 1.25]

0.73

[ 0.51 , 1.05]

2013
2014

0.88

[ 0.67 , 1.17]

0.75

[ 0.53 , 1.08]

0.82

[ 0.62 , 1.08]

0.96

[ 0.69 , 1.34]

2015

[ref]

[ref]

[ref]

65 to 69 years

[ref]

[ref]

[ref]

70 to 74 years

1.42

[ 1.13 , 1.77]

0.002

1.11

[ 0.81 , 1.52]

0.92

[ 0.63 , 1.35]

75 to 79 years

1.81

[ 1.42 , 2.30]

<0.001

1.16

[ 0.84 , 1.59]

0.95

[ 0.65 , 1.40]

≥80 years

2.47

[ 1.99 , 3.06]

<0.001

1.22

[ 0.92 , 1.62]

0.74

[ 0.53 , 1.04]

Female

1.02

[ 0.86 , 1.21]

1.81

[ 1.48 , 2.22]

1.88

[ 1.46 , 2.44]

Male

[ref]

[ref]

[ref]

White

[ref]

[ref]

[ref]

Non-Whites

1.03

Prob

Year of diagnosis

Age

Sex
<0.001

<0.001

Race
[ 0.68 , 1.55]

0.62

[ 0.34 , 1.14]

0.63

[ 0.32 , 1.24]

Marital status
Married

[ref]

Not married

0.91

[ref]
[ 0.77 , 1.07]

0.79

[ref]
[ 0.65 , 0.97]

0.03

0.58

[ 0.42 , 0.80]

0.001

1.85

[ 1.41 , 2.43]

<0.001

Region
Northeast

[ref]

South

0.89

[ 0.68 , 1.18]

[ref]

[ref]

North central

0.65

[ 0.47 , 0.90]

0.009

1.13

West

0.67

[ 0.53 , 0.85]

0.001

0.82
0.99

[ 0.58 , 1.69]

0.93

[ 0.62 , 1.38]

[ 0.80 , 1.59]

1.42

[ 0.91 , 2.21]

[ 0.63 , 1.06]

0.79

[ 0.56 , 1.12]

3.33

[ 2.14 , 5.19]

Dual Medicare /Medicaid Enrollment
Yes

1.31

No

[ref]

[ 0.82 , 2.07]

[ref]

[ref]

Note: Based on 4,519 older adults with incident late-stage (Stage III/IV) melanoma continuously enrolled in
Medicare Parts A and B fee-for-service programs 12 months prior to incident cancer diagnosis.
AD: Autoimmune diseases; MHC: Mental health conditions; PHC: Physical health conditions; Prob: Probability
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<0.001

CHAPTER 3
3. FACTORS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITOR USE
AMONG OLDER PATIENTS WITH LATE-STAGE MELANOMA
3.1. Abstract
Background: Improvement in overall survival by immune checkpoint inhibitors (ICI)
treatment in clinical trials encourages their use for late-stage melanoma. However, in the realworld, heterogeneity of population, such as elderly with multimorbidity, may lead to a slower
diffusion of ICIs. The objective of this study was to examine the association of multimorbidity
and other factors to ICI use among older patients with late-stage melanoma using real world data.
Methods: A retrospective cohort study design with a 12-month baseline and follow-up
period was adopted with data from the linked Surveillance, Epidemiology, and End Results
cancer registry/Medicare database. Older patients (>65 years) with late-stage (stage III/IV)
melanoma diagnosed between 2012 and 2015 were categorized as with or without
multimorbidity (presence of two or more chronic conditions) and ICI use was identified in the
post-index period. Chi-square tests and logistic regression were used to evaluate factors
associated with ICI use.
Results: In the study cohort, 85% had multimorbidity, 18% received any treatment
(chemotherapy, radiation, and/or ICI), and 6% received ICI. Only 5.5% of older patients with
multimorbidity and 6% without multimorbidity received ICIs. Younger age, presence of social
support, lower economic status, residence in northeastern regions, and recent year of diagnosis
were significantly associated with ICI use; however, multimorbidity, sex, and race were not
associated with ICI use.
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Conclusions: In the real-world clinical practice, only one in 18 older adults with late
stage melanoma received ICI, suggesting slow pace of diffusion of innovation. However,
multimorbidity was not a barrier to ICI use.
3.2. Introduction
Newer therapies, namely immune checkpoint inhibitors (ICIs) with a unique mechanism
of action and unknown side effect profile,92 have significantly increased the survival prognosis
for adults with late-state melanoma.19,22,93 The first ICI was approved in 2011 by the United
States (US) Food and Drug Administration and has since been recommended as the first-line
treatment for late-stage melanoma by the National Cancer Comprehensive Network (NCCN)
guidelines.42,93 These recommendations were based on the evidence presented in randomized
clinical trials (RCTs), which have strict inclusion and exclusion criteria.19,20,72 These stringent
criteria, while beneficial to ensure patient safety, do not capture the heterogeneity of various
patient subpopulations.
This lack of information on heterogeneity of treatment effects may be a reason that
despite being around for nearly a decade, the uptake of ICI in the real-world setting is dismal.94
One of the patient subpopulations where evidence on use of ICI is lacking is the elderly.
Although utility of ICI in elderly patients with late-stage melanoma is debated, data from studies
have shown that these therapies are well tolerated in the elderly.95–97 Older patients are also
known to have multiple chronic conditions (also known as multimorbidity), which are often not
taken into account by the guidelines.95,96,98 There are no studies to-date examining the
association of multimorbidity on treatment with ICI among older individuals with late-stage
melanoma. Presence of multimorbidity leads to less aggressive treatment with existing
modalities (such as chemotherapy and radiation) due to fear of worsening other conditions.32,33,35
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Older patients with multimorbidity are the norm rather than exception in clinical practices.29
Therefore, evaluating the association of multimorbidity to ICI use in real-world setting may help
healthcare providers personalize these treatments for their older patients.
In addition, disparities in the receipt of ICI are unknown. Studies on other cancers have
shown some subgroups may be less likely to receive treatment. For example, age and racial
disparities on treatment received was reported among older patients with late-stage pancreatic
adenocarcinoma.46 Patients below the age of 80 years and White non-Hispanics were more
likely to receive treatment than those above 80 years of age and other race/ethnicity.46 Similarly,
a study among older patients with bladder cancer reported better survival among married patients
than unmarried ones, because of greater likelihood of receiving treatment.47 Underinsured
patients with late-stage melanoma were more likely to receive treatment at lower immunotherapy
prescribing hospitals.48 With evident disparities in receipt of treatment, it is critical to know
whether some subgroups lag in the diffusion of innovative therapies like ICIs, so that oncologists
and patients alike can make informed decisions when considering ICIs as the treatment option.
Therefore, the objective of this study is to examine the association of multimorbidity and other
factors to ICI use that cover years from the initial introduction (i.e. 2011) to 2015 among older
patients with late-stage melanoma.
3.3. Methods
Study Design
This was a retrospective cohort design with a 12-month baseline (pre-diagnosis) and
12-month follow-up (post-diagnosis) period. Diagnosis date of late-stage (stage III/stage IV)
melanoma diagnosis was used to define pre- and post-diagnosis periods. Multimorbidity and all
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independent variables were assessed in the baseline period while treatments (chemotherapy,
radiation, ICI) received were assessed in the follow-up period.
Data Source
This study was conducted using the Surveillance, Epidemiology, and End Results
(SEER) cancer registry linked with fee-for-service Medicare claims. Information on clinical
variables related to cancer (such as stage of cancer at diagnosis) was obtained from SEER data,
while information on healthcare encounters of beneficiaries when enrolled and using Medicare
covered health services was obtained from Medicare claims.
Study Population
Incident melanoma diagnosis between 2011 and 2015 was identified using ICD-O-3 site
codes (C44.0 – C44.9) and ICI-O-3 histology codes (8720 – 8790). Late-stage (stage III/IV) of
melanoma was identified based on the TNM classification using American Joint Committee on
Cancer 7th Edition. The final cohort comprised of 4,519 patients with late-stage melanoma
following exclusion of those with local or regional (stage I/II) melanoma, non-incident
melanoma, ages 66 years and below, not continuously enrolled in Medicare part A and part B
during pre-index period, and diagnosed with late-stage cancer during autopsy.
Measures
Dependent variable: ICI use
The study outcome, ICI use, was identified in the post-diagnosis period. The ICIs
approved for late-stage melanoma treatment include ipilimumab, nivolumab, and
pembrolizumab, which were identified using healthcare common procedure coding system
(HCPCS) codes (J9228, J9299, J9271).
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Independent variables
Multimorbidity: Presence of two or more chronic conditions in the pre-diagnosis period
was defined as multimorbidity in this study. These conditions were obtained from a list of 18
chronic conditions developed by Multiple Chronic Conditions working group within the US
Department of Health and Human Services Office of Assistant Secretary of Health. Pre-existing
autoimmune diseases were also added to the list based on the current challenges with ICI use in
patients with these conditions.73 All these conditions were identified with International
Classification of Diseases (ICD), 9th Edition.
Treatment with chemotherapy and radiation was also determined in the post-index period.
Chemotherapy and radiation claims were identified using procedure codes, HCPCS codes, and
revenue center codes (see Appendix 7.2). Overlapping procedure codes for chemotherapy and
ICI (96413, 96415) were excluded to avoid confusion.
Biological factors consisted of age (66-69 years, 70-74 years, 75-79 years, and ≥80
years), sex (male/female), and race (white/non-white). Social factors included marital status
(married/not married). Community resources included regions (Northeast, South, West, and
North Central). Dual Medicare/Medicaid enrollment (yes/no) was used as a proxy for low
economic status. Years of incident melanoma diagnosis (2012-2015) was used to control for
changes in practice patterns.
Statistical Analysis
Chi-square tests were used to identify significant unadjusted associations of individual
characteristics to ICI use. Multivariable Logistic regressions were performed to determine the
association of multimorbidity, year of diagnosis, age, sex, race/ethnicity, marital status, dual
eligibility, and region with ICI use. Parameter estimates are presented as adjusted odds ratios
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(AORs) after adjusting for all independent variables, with their corresponding 95% confidence
intervals (CI); p ≤ 0.05 was considered statistically significant. All analyses were conducted
using SAS 9.4 (SAS Institute Inc.).
3.4. Results
The study population comprised predominantly of males (64.2%), Non-Hispanic Whites
(96.1%) and those 70 years or older (70.4%). About 85% of the older adults had multimorbidity,
18% received any treatment, and 6% received ICI. In the study cohort, 5.5% of patients with
multimorbidity and 6% of patients without multimorbidity received ICI. The characteristics of
those who received and did not receive ICI differed by all variables except the presence of
multimorbidity (p=0.62) and race (p=0.29) (Table 3.1).
Factors associated with ICI use: Unadjusted Logistic Regression on ICI use
Table 3.2 presents the unadjusted odds ratio (OR), AORs, and 95% CIs of all
independent variables included in the study from separate logistic regressions on ICI use. In the
unadjusted regressions, year of diagnosis, age, sex, marital status, and dual eligibility were
significantly associated with ICI use.
Factors associated with ICI use: Multivariable Logistic Regression on ICI use
Patients in the lower age groups (66 to 69 years and 70 to 74 years) had significantly
higher odds of receiving ICIs than those 80 years and above (AOR=1.65, 95%CI=1.15, 2.36;
AOR=1.81, 95%CI=1.28, 2.54 respectively). Patients who were married (AOR=1.92,
95%CI=1.46, 2.52), resided in the Northeastern SEER regions (AOR=1.75, 95%CI=1.26, 2.41),
and had dual eligibility (AOR=2.42, 95%CI=1.40, 4.19) were more likely to receive ICIs than
the comparison groups: those who were not married, residing in SEER Western regions, and did
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not have dual eligibility. Patients diagnosed in 2012 (AOR=0.42, 95%CI=0.28, 0.63) were less
likely to receive ICI than those diagnosed in 2015.
Multimorbidity was not significantly associated with ICI in fully adjusted models. In the
fully adjusted model, sex and race were not significantly associated with ICI use.
3.5. Discussion
The treatment landscape for late-stage melanoma remained unchanged for decades before
the introduction of ICIs in 2011. The median overall survival with traditional treatments
(chemotherapy and/or radiation) is 6 to 8 months.99,100 Due to poor prognosis for survival, many
patients may not receive treatment, as observed in this study. An overwhelming majority (82%)
of the cohort did not receive any treatment for their late-stage melanoma. Post-late stage
melanoma diagnosis treatment rates (18%) observed in this study is consistent with a published
study (22%).101 In this published study, the authors noted 22% initiated treatment after the
disease progression while 51% started treatment before late-stage melanoma diganosis.101
Although ICIs have been around for nearly a decade, evidence on the treatment pattern in
the real world is just emerging. Recent studies exploring the real-world treatment patterns
among all adults for late-stage melanoma reported that only 34-37% of the patients received ICI
as the first-line treatment, despite the recommendation by the NCCN guidelines.25,102,103 The
rates of treatment with ICI in our study is very low (6%). A plausible reason for the low rate can
be due to the differences in population studied. Our study focused on older adults with 85%
having pre-existing multimorbidity who may be at high risk for poor survival prognosis. As
evidence is still emerging on the side effect profile of ICIs compared to existing modalities,104
oncologists may be cautious in using ICI among older patients with late-stage melanoma.
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This study observed that an overwhelming majority of patients had pre-existing
multimorbidity, no different than other cancer types.32,105 As RCTs of ICIs typically exclude
patients with multimorbidity, 106 evidence on the association of multimorbidity to ICI use is not
available. This is the first study to report the use of ICI among older patients with
multimorbidity status. In this study, those with multimorbidity were as likely to receive ICI as
those without, suggesting that multimorbidity was not a barrier in the receipt of ICI. While the
rationale for this was not explored further, plausible reasons are discussed. Recent studies using
SEER-Consumer Assessment of Healthcare Providers and Systems suggest that patients with
multimorbidity and cancer have better communication with their providers and rated specialties
better than those without multimorbidity.107 It has also been reported that elderly Medicare
beneficiaries with multimorbidity are equally likely to trust their doctors for their care,108
suggesting that multimorbidity may not be a barrier to novel life-saving therapies.
This is the first study to the best of our knowledge that explored the factors associated
with ICI use among the elderly with late-stage melanoma. In this study, compared to patients
80 years and older, those between the ages of 66 and 74 years were more likely to receive ICIs.
However, published studies did not find additional adverse events or difference in overall
survival in patients between 80 to 100 years versus those between 65 to 79 years, when treated
with ICIs.96 Oncologists may exercise caution in active treatment of cancer among old-old (age
> 80 years), because side effects can occur more often and in greater severity in this age
group.105,109,110 Furthermore, higher rates of pre-existing chronic conditions in this age group
may also warrant cautious active cancer treatment. In our study, nearly 90% of those 80 years or
older had pre-existing multimorbidity compared to only 82% among 65 to 79 years. Due to
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small cell sizes, we were unable to empirically test the interaction of old-old with multimorbidity
on ICI use in our study.
In this study, social support, measured with the proxy (i.e. marital status), was
significantly associated with ICI use. Presence of social support have shown lesser
psychological distress among patients with cancer and more enthusiasm about getting treatment,
even if the disease is terminal.111,112 Therefore, these patients are more accepting of newer
treatments. It is plausible that shared decision making with the patient and their
caregivers/support system may increase the use of novel therapies in real-world settings.
Regional variations were also observed in our study, with older patients residing in
Northeastern SEER regions having higher rates of ICI use. The reasons for differential adoption
of newer treatments across the US regions is complex. Although to date, no study has examined
regional disparities in ICI use among late-stage melanoma patients, few reasons for regional
disparities based on evidence from the adoption of new medical treatments and new technologies
are speculated here. The US states with higher population density may also have greater number
of highly skilled professionals. In addition, these states tend to have policies that provide more
opportunities to capitalize on innovations and are more likely to adopt innovations faster.113,114
Based on these factors, states in the Northeastern region including New York, Connecticut, and
Massachusetts, had the highest innovation scores compared to other US states.113 In addition,
key opinion leaders, who also lead many RCTs, play an important role in the diffusion of
innovation.115 A study reported that such opinion leaders were based in urban areas, most of
them in the Northeastern regions such as New York City and Boston.115 These leaders
encouraged use of innovative therapies in real-world settings.115 Healthcare providers in various
US regions should, therefore, evaluate the political influences in driving their prescribing
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practices and work with local opinion leaders in finding ways to improve adoption of newer
therapies among patients.
In this study, dual Medicaid/Medicare eligibility was positively associated with ICI use.
Previous studies have reported that dually eligible beneficiaries are less likely than Medicareonly beneficiaries to receive prostate or breast cancer treatment.116 In a study of lung cancer
patients, dual eligibility status was associated with longer duration of treatment.117 Recent
studies on late-stage melanoma reported that patients with Medicaid were less likely to receive
ICIs and those with Medicare were as likely to receive ICIs as patients with commercial
insurance.118–120 Thus, the receipt of ICI may be driven more by Medicare than Medicaid.
Year of diagnosis was significantly associated with ICI use, with those diagnosed in
earlier years being less likely to use ICIs. This may be because of few completed RCTs at the
time and only one ICI (ipilimumab) approved for the treatment before 2014. Therefore, the data
to support the safety and efficacy of ICI had not been widely been disseminated. In addition, the
diffusion of innovation takes substantial time.94 Rather than rely on communication of a medical
innovation, most physicians adopted the innovation after watching their colleagues use them.121
This is especially true when contemplating use in populations excluded in the RCTs,121 such as
older patients with multimorbidity. Although the use of ICI as first-line treatment in late-stage
melanoma was added in NCCN guideline in 2012, studies on the use of ICI in real-world settings
remain limited.
3.6. Strengths and limitations
The findings of this study should be interpreted considering its limitations. First, the
reasons for not receiving any treatment in older patients was unknown. Though disparities in ICI
use were observed, we are unable to evaluate whether these disparities are due to patient

39

preferences or shared decision-making of providers and patients. Such information could direct
healthcare providers on measures that can be taken to enhance the adoption of ICIs. Second,
individual-level socioeconomic factors, such as education and income, which may be associated
with ICI use, were not available to us. Third, information on severity of co-existing illnesses
may have provided insights into whether the intake is low because of competing demands that
may confer high mortality risk and may have precluded the use of ICI. Despite these limitations,
the study has several strengths. No study to-date has focused on treatment of older adults with
multimorbidity and late-stage melanoma. With a high prevalence, oncologists are bound to
encounter such patients on a daily basis. This study provides oncologists with strong evidence on
the current treatment landscape among older adults with multimorbidity. In addition, this study
examined the factors associated with ICI use. In the era of personalized medicines, patient-level
factors play a critical role in treatment decisions. This study sheds light on various factors that
will help healthcare providers in reaching a successful treatment goal with their older patients.
3.7. Conclusions
The findings from this study suggest that despite evidence of improved survival benefits
over chemotherapy, the adoption of ICI among older patients remain low. This study revealed
disparities in ICI use even after five years since ICI approval and introduction in the US markets.
However, multimorbidity was not a barrier to ICI use suggesting that future research is needed
on low uptake of ICI in older patients with multimorbidity.
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TABLES
Table 3.1
Percent with Immune Checkpoint Inhibitor (ICI) use by Selected Patient-level
Characteristics among Older Adults (age >65 years) with Incident Late-stage
Melanoma during 2012 and 2015
Linked Surveillance, Epidemiology, and End Results and Medicare Claims Database
ICI
No ICI
Variables
%
%
p-value
Significance
ALL
5.6
94.4
Multimorbidity
Yes
5.5
94.5
0.62
No
6.0
94.0
Year of diagnosis
2012
3.2
96.8
0.0008
***
2013
5.8
94.2
2014
6.4
93.6
2015
6.8
93.2
Age
66 to 69 years
6.8
93.2
0.0004
***
70 to 74 years
7.6
92.4
75 to 79 years
5.0
95.0
≥80 years
4.1
95.9
Sex
Female
4.5
95.5
0.014
*
Male
6.2
93.8
Race
Whites
5.5
94.5
0.29
Non-Whites
7.3
92.7
Marital Status
Married
7.3
92.7
<0.0001
***
Not married
3.9
96.1
Dual Medicare/Medicaid eligibility
Yes
10.0
90.0
0.0104
*
No
5.4
94.6
Regions
Northeast
7.9
92.1
0.0186
*
South
5.1
94.9
North Central
5.1
94.9
West
5.1
94.9
Note: Based on 4,519 older adults with incident late-stage (Stage III/IV) melanoma
continuously enrolled in Medicare Part A & B fee-for service programs 12 months prior
to incident cancer diagnosis. *0.05< p ≤ 0.01; **0.01 < p ≤0.001; *** p< 0.001
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Table 3.2
Unadjusted Odds Ratio (OR), Adjusted Odds Ratios (AOR), and 95% Confidence Intervals (CI) from Logistic
Regressions on Immune Checkpoint Inhibitor use
Older Adults (age >65 years) with Incident Late-stage Melanoma during 2012 and 2015
Linked Surveillance, Epidemiology, and End Results and Medicare Claims Database
Unadjusted analysis
Fully Adjusted Analysis
Variables
OR
95%CI
Significance
AOR
95%CI
Significance
Multimorbidity
Yes
0.82
0.96
[ 0.55 , 1.22 ]
[ 0.67 , 1.37 ]
No
(ref)
(ref)
Year of diagnosis
2012
(ref)
(ref)
2013
2.03
[ 1.30 , 3.18 ]
**
1.82
[ 1.19 , 2.78 ]
**
2014
1.98
[ 1.27 , 3.09 ]
**
2.10
[ 1.39 , 3.18 ]
***
2015
0.78
[ 0.45 , 1.34 ]
2.38
[ 1.58 , 3.59 ]
***
Age
65 to 69 years
1.82
[ 1.19 , 2.81 ]
**
1.63
[ 1.14 , 2.34 ]
**
70 to 74 years
2.19
[ 1.46 , 3.28 ]
***
1.79
[ 1.27 , 2.52 ]
***
75 to 79 years
1.42
[ 0.90 , 2.25 ]
1.18
[ 0.80 , 1.74 ]
>80 years
(ref)
(ref)
Sex
Females
0.67
[ 0.48 , 0.94 ]
*
0.78
[ 0.58 , 1.04 ]
Males
(ref)
(ref)
Race
Whites
(ref)
(ref)
Non-whites
1.53
[ 0.79 , 2.94 ]
1.17
[ 0.64 , 2.15]
Marital Status
Married
1.99
[ 1.45 , 2.73 ]
***
1.94
[ 1.48 , 2.56 ]
***
Not married
(ref)
(ref)
Dual Medicare/Medicaid eligibility
Yes
1.99
[ 1.08 , 3.66 ]
*
2.34
[ 1.35 , 4.03 ]
**
No
(ref)
(ref)
Region
North central
0.65
[ 0.36 , 1.17 ]
0.59
*
[ 0.36 , 0.95 ]
West
0.72
[ 0.49 , 1.06 ]
0.57
[ 0.42 , 0.79 ]
***
South
0.64
[ 0.40 , 1.02 ]
0.56
[ 0.38 , 0.83 ]
**
Northeast
(ref)
(ref)
Note: Based on 4,519 older adults with incident late-stage (Stage III/IV) melanoma continuously enrolled in Medicare
Parts A and B fee-for-service programs 12 months prior to incident cancer diagnosis. *0.05< p ≤ 0.01; **0.01 < p
≤0.001; *** p< 0.001
Abbreviations: ref = Reference group
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CHAPTER 4
4. IMMUNE CHECKPOINT INHIBITOR USE, MULTIMORBIDITY, AND
HEALTHCARE EXPENDITURES AMONG OLDER ADULTS WITH LATE-STAGE
MELANOMA
4.1. Abstract
Background: The objective of this study is to assess the impact of immune checkpoint inhibitors
(ICI) and multimorbidity on healthcare expenditures among older patients with late-stage
melanoma.
Methods: A retrospective longitudinal cohort study using Surveillance, Epidemiology, and End
Results linked with Medicare claims was conducted. Generalized linear mixed models were
used to analyze adjusted relationships of ICI, multimorbidity, and ICI-multimorbidity interaction
on average healthcare expenditures.
Results: Patients who received ICI and those who had multimorbidity had significantly higher
average total healthcare expenditures compared to ICI nonusers and no multimorbidity. In the
fully adjusted model using ICI-multimorbidity interaction, no excess cost was added by
multimorbidity.
Conclusion: Use of ICIs, regardless of multimorbidity, is associated with increased healthcare
expenditures.
4.2. Introduction
Cancer exerts a substantial burden on the morbidity and mortality of patients.122,123 In
addition, cancer exerts a significant economic burden on not only the patients, but also on payers
and society as well.50 Cancer is one of the top five most expensive chronic conditions.50 There
is robust evidence showing that cancer substantially increases healthcare expenditures.124–127 For
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example, it has been reported that adults with cancer have four times higher expenditures
compared to those without cancer.51,127 Furthermore, the healthcare cost of cancer differs by the
type and stage of cancer. Healthcare costs were highest for cancers with poor survival rates such
as brain cancers and lowest for cancers with high survival rates, such as melanoma.51 However,
the cost increases substantially when the cancer metastasizes.50–52 For example, 55% of the
annual direct costs for treating melanoma were related to treating late-stage melanoma.53
While many factors can influence healthcare costs among cancer patients, expensive
drugs approved for cancer, the administration of these drugs, and supportive care (monitoring,
surveillance, and management of side-effects such as kidney infections, pneumonia through
frequent medical office visits and sometimes hospitalizations) are some of the main factors.56
For example, in metastatic melanoma patients initiated on an immune therapy agent ipilimumab,
the average all-cause healthcare expenditures for a treatment episode was estimated to be
$153,062.128 The immune checkpoint inhibitors (ICIs) were first approved for the treatment of
late-stage melanoma nine years ago after their success in improving survival was established by
randomized clinical trials (RCTs).92 However, the high cost of ICIs may hinder their widespread
adoption in real-world clinical settings. The average wholesale price in 2015 of a single dose for
a 70 kg patient was $5,732 for nivolumab, $33,162 for ipilimumab, and $35,073 for the
combination therapy.129 As these drugs need to be administered by healthcare professionals in
outpatient settings, the total costs are even higher.130 This is compounded by the fact that an
optimum dose for ICIs remains unknown which entails continuous use of ICI until regression of
the tumor or appearance of adverse events.20,21,23 Oncologists estimated that treatment cost for
the highest and most often administered dose, 26 courses of an ICI can be as high as $1,009,944
with a 20% copay.57
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Thus, a vast majority of patients cannot afford ICI treatment unless covered by health
insurance.48,120,131,132 In the United States (US), insurance and type of insurance coverage are
often associated with prognosis, treatment and survival of cancer patients. Specifically, using the
National Cancer Database, Jain and coauthors (2020) reported that the stage of diagnosis and
receipt of ICIs were associated with insurance status.133 A high proportion of individuals with
late-stage melanoma were on Medicare and were as likely as those with commercial insurance to
receive ICI.48,49 These findings suggest that Medicare may bear a disproportionate share of latestage melanoma expenditures. Furthermore, older Medicare beneficiaries (age > 65 years) are of
particular interest for several reasons; 96% are covered by Medicare; higher incidence of better
cancer/late-stage melanoma is observed among these patients, and Medicare patients are facing
an evolving payment landscape, such as Oncology Care Model (OCM), aimed towards
improving cancer care continuum while reducing costs in older patients.10,134–136
The newer payment models also include patients in high-risk groups, such as those with
multimorbidity.136 This is because 68% of the Medicare population reported having
multimorbidity and resulted in 80% of Medicare payments.29,137–139 Expert and systematic
reviews have concluded that patients with multimorbidity have higher costs compared to those
without multimorbidity.28,140 Patients with multimorbidity and cancer have higher expenditures
compared to those without any multimorbidity.141,142 Furthermore, multimorbidity is highly
prevalent in older adults with late-stage melanoma.143 If ICI are added to this mix, patients with
multimorbidity and ICI may have even higher costs than those without multimorbidity and ICI.
Therefore, the objectives of this study are (a) to estimate the impact of ICI use and (b) to assess
the impact of the interaction of ICI and multimorbidity on healthcare expenditures among older
patients with late-stage melanoma. We hypothesize that ICI use will be associated with high
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expenditures throughout the treatment period compared to those without ICI use, and those with
multimorbidity and ICI will have even higher costs than those without multimorbidity and ICI.
4.3. Methods
Study design
A retrospective observational longitudinal cohort design with a 12-month baseline (preindex) and a 12-month follow-up (post-index) period was used; incident diagnosis of late-stage
(stage III/IV) melanoma diagnosis was defined as the index date. Independent variables were
assessed in the baseline period while treatments (chemotherapy, radiation, ICI) received were
assessed in the follow-up period. Healthcare expenditures were measured every 120 days (t1, t2,
t3, t4, t5, and t6) during the 24-month observation period to ensure robust findings by reducing the
“signal-to-noise” ratio144 (Figure 4.1).
Data Sources
Surveillance, Epidemiology, and End Results (SEER) cancer registry linked with fee-forservice Medicare claims was used as the data source. Information on clinical variables related to
cancer (such as stage of cancer at diagnosis) was obtained from the SEER data. Information on
healthcare encounters of beneficiaries when enrolled and using Medicare covered health services
including Medicare payments, and provider settings was obtained from Medicare claims.
Study Population
The study population was comprised of older (>65 years) adults diagnosed with incident
melanoma between 2012 and 2015, identified using ICD-O-3 site codes (C44.0 – C44.9) and
ICI-O-3 histology codes (8720 – 8790). Late-stage (stage III/IV) of melanoma was identified
based on the TNM classification using American Joint Committee on Cancer 7th Edition. After
excluding patients with local or regional (stage I/II) melanoma, non-incident melanoma, ages
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66 years and below, not continuously enrolled in fee-for-service Medicare part A and part B
during the observation period, and diagnosed with late-stage cancer during autopsy, the final
cohort consisted of 4,519 patients.
Measures
Dependent variable: Total and Type of Healthcare expenditures
Total healthcare expenditures consisted of the sum of Medicare payments for inpatient,
outpatient services (including carrier claims) for any care, home health care, and durable medical
equipment. We also analyzed type of healthcare expenditures by site of care (inpatient and
outpatient, and home healthcare). All healthcare expenditures were adjusted by the Consumer
Price Index for medical services145 and expressed in 2016 USD.
Independent variables
The use of ICI (yes/no) was identified in the post-diagnosis period. The three ICIs
approved for late-stage melanoma treatment, ipilimumab, nivolumab, and pembrolizumab, were
identified using healthcare common procedure coding system (HCPCS) codes (J9228, J9299,
J9271). Overlapping procedure codes for chemotherapy and ICI (96413, 96415) were excluded
to ensure that chemotherapy was not misclassified as ICI.
Multimorbidity (yes/no) was defined as the presence of two or more chronic conditions in
in this study. These conditions were obtained from a list of 18 chronic conditions developed by
Multiple Chronic Conditions working group within the US Department of Health and Human
Services Office of Assistant Secretary of Health.41 Pre-existing autoimmune diseases were
added to the list based on the current challenges with ICI use in patients with these conditions.42
All the chronic conditions were identified with International Classification of Diseases (ICD),
9th Edition.
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To examine the effects of ICI-multimorbidity interaction on cost, an ICI-multimorbidity
interaction term was created, which was categorized into 4 groups: ICI and multimorbidity, ICI
and no multimorbidity, No ICI and multimorbidity, and No ICI and no multimorbidity.
Other independent variables included biological factors, social factors, community
resources, economic status, and year of diagnosis. Biological factors consisted of age (66-69
years, 70-74 years, 75-79 years, and ≥80 years), sex (male/female), and race (white/non-white).
Social factors included marital status (married/not married). Oncologist visits (yes/no) and
primary care physician visits (yes/no) were measured every 120 days. Dual Medicare/Medicaid
enrollment (yes/no) was used as a proxy for low economic status. Years of incident melanoma
diagnosis (2012-2015) was used to control for changes in practice patterns.
Statistical Analyses
Unadjusted subgroup differences in time-invariant characteristics between ICI users were
tested with chi-square statistics. The associations of ICI and multimorbidity to healthcare
expenditures were tested within the framework of Generalized Linear Models (GLM) with
gamma distribution and log-link. This specification was chosen for GLM because of several
reasons: (a) GLM does not require normal distribution of errors, (b) better aligns the variance
function to the mean function, and (c) does not require smearing correction, which can be easily
converted to original dollars.43 Modified Park test confirmed the choice of gamma distribution
with log-link was selected. As healthcare expenditures were measured every 120 days during the
pre- and post-index periods, each individual had six observations. However, these observations
were not independent and therefore generalized linear mixed models (GLMMs) with gamma
distribution and log-link was used to analyze adjusted relationships between ICI and non-ICI
user groups and ICI-multimorbidity interaction. The GLMMs included all independent variables
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and time. Both unadjusted and adjusted models used GLMMs. Adjusted GLMMs included a
time squared as one of the independent variables, to control for the non-linear relationship of
healthcare expenditures over time. All analyses were conducted on STATA (StataCorp 2015).
4.4. Results
The study population was comprised of predominantly of males (64.2%), Non-Hispanic
Whites (96.1%) and those 70 years or older (70.4%). Most older patients with late-stage
melanoma had multimorbidity (85%) and 6% received ICI. The mean time from index date to
ICI initiation was 48 days. The characteristics of the study population are presented in
Appendix 7.3.
Overall healthcare expenditures
The average total, outpatient, home health, and inpatient healthcare expenditures in the
pre-index period (t1, t2, and t3) were significantly (p < 0.001) lower than the expenditures in the
post-index period (t4, t5, and t6) (Figure 4.2). All healthcare expenditures in the 120-day postlate-stage melanoma diagnosis period (t4) were significantly higher compared to other pre- and
post-index time periods (t1, t2, t3, t5 and t6).
Healthcare expenditures among ICI users and non-users
The average total, outpatient, home healthcare, and inpatient healthcare expenditures
were significantly higher among ICI users compared to non-ICI users. Among ICI users, the
average total and inpatient expenditures were significantly higher in t4 (representing 120 days
after cancer diagnosis) compared to other time periods (t1, t2, t3, t5 and t6) while average
outpatient and home healthcare expenditures did not differ significantly in t4 and t5 and t4 and t6
time periods, respectively. Among non-ICI users, average total, outpatient, home healthcare, and
inpatient expenditures were significantly higher in t4 compared to other time periods.
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Healthcare expenditures among those with and without multimorbidity
The average total, outpatient, home healthcare, and inpatient healthcare expenditures
were significantly higher among those with multimorbidity compared to those without
multimorbidity. Compared to t4, the average total, outpatient, home healthcare, and inpatient
expenditures were significantly lower in other time periods (t1, t2, t3, t5 and t6) among those with
multimorbidity. The average home healthcare expenditure did not significantly differ in t4 and t6
time periods among those without multimorbidity.
Healthcare expenditures and ICI-multimorbidity interaction
The average total, outpatient, home healthcare, and inpatient healthcare expenditures
were significantly higher among ICI users and with multimorbidity group compared to ICI nonusers and without multimorbidity. Average total expenditures by the ICI-multimorbidity groups
are displayed in Figure 4.3. Compared to t4, the average total, outpatient, home healthcare, and
inpatient expenditures were significantly lower in other time periods (t1, t2, t3, t5 and t6) among
ICI users and with multimorbidity.
Adjusted associations of ICI and multimorbidity to total healthcare expenditures
Table 4.1 presents the unadjusted and adjusted parameters of GLMM on average total
healthcare expenditures. The unadjusted and fully adjusted models showed similar results. In
the model that was adjusted for time and time-squared, those with ICI had significantly higher
average expenditures than those without ICI (β=1.34, SE=0.52, p <0.001). When adjusted for
multimorbidity, ICI users and those with multimorbidity had higher average expenditures
compared to ICI non-users or no multimorbidity. In the fully adjusted model, the average total
expenditure significantly increased with time (β=0.49, SE=0.04, p < 0.001). Patients who
received ICI (β=0.91, SE=0.07, p < 0.001) and those who had multimorbidity (β=0.72, SE=0.07,
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p < 0.001) had significantly higher average total expenditures compared to those who did not
receive ICI or did not have multimorbidity.
Other variables with significant findings were age, dual eligibility, and visits to
oncologists and primary care physicians. Significantly higher average total expenditures were
reported in patients aged 75 to 79 years (β=0.17, SE=0.07, p = 0.015) and 80 years and older
(β=0.26, SE=0.06, p < 0.001) compared to those aged between 65 and 69 years, who were dual
eligible (β=0.28, SE=0.11, p = 0.011) versus those who were not, who had visited oncologists
(β=1.75, SE=0.05, p < 0.001) versus no oncologist visits, and who had visited primary care
physician (β=1.38, SE=0.05, p < 0.001) versus no primary care physician visits.
We also conducted GLMM on average total expenditures by ICI-multimorbidity
interaction. In the fully adjusted model, compared to no ICI/no multimorbidity, average total
expenditures were significantly higher in all other groups, namely in patients who used ICI and
had multimorbidity (β=17889.18, SE=1260.794, p < 0.001), who used ICI but did not have
multimorbidity (β=16178.22, SE=2951.45, p < 0.001), and who did not use ICI but had
multimorbidity (β=1510.35, SE=368.74, p < 0.001). The contrast in average healthcare
expenditures was examined by ICI use and multimorbidity by using ICI-no multimorbidity as the
comparator group (Table 1). In the fully adjusted model, the average total healthcare
expenditure significantly increased with time (β=0.50, SE=0.04, p < 0.001). Patients who were
non-ICI users and had multimorbidity (β=-0.73, SE=0.14, p < 0.001) and non-ICI users and with
no multimorbidity (β=-1.51, SE=0.15, p < 0.001) had significantly lower costs compared to
patients who were ICI users and had no multimorbidity. However, there was no significant
difference between patients who were ICI users and had multimorbidity and patients who were
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ICI users and had no multimorbidity. Other variables with significant findings were same as
above.
Adjusted relationships between ICI, multimorbidity, and type of healthcare expenditures
The relationship between ICI and multimorbidity by type of expenditures (outpatient,
home healthcare, and inpatient) was further explored. The findings for average outpatient
expenditures were similar to total expenditures (Appendix 7.4).
While patient with multimorbidity had significantly higher average home healthcare and
inpatient expenditures compared to those without multimorbidity, ICI use was not significantly
associated with those expenditures (Appendix 7.5 and Appendix 7.6, respectively). Similarly, the
unadjusted and adjusted models of the effect of ICI and multimorbidity interaction on average
home healthcare and inpatient expenditures were similar. In the fully adjusted model, the
average home healthcare (β=0.19, SE=0.06, p = 0.002) and inpatient expenditure (β=1.56,
SE=0.22, p < 0.001) significantly increased with time. However, no significant difference was
observed among the ICI and multimorbidity groups.
4.5. Discussion
This study confirms previous findings and also presents some new findings. First, this
study reports that average healthcare expenditures significantly increased after a terminal cancer,
i.e., late-stage melanoma, diagnosis, which is in line with published studies. Cancer diagnosis
exerts a huge financial burden on patients, payers, and healthcare systems, with four times higher
costs in cancer cohort compared to the non-cancer cohort.3,7 Late-stage cancers tend to be more
expensive than early-stage cancers.4,8,44,45 Although costs of early-stage versus late-stage
melanoma were not compared, these findings still relay that late-stage melanoma diagnosis
among older patients places enormous burden on the payers. These findings have implications
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for the new OCM that are being experimented by the CMS. Under the OCM providers are
expected to “provide higher quality, more highly coordinated oncology care at the same or lower
cost to Medicare”.29 The OCM organizes care around six-month episodes.29 By providing
information on total healthcare expenditures by time periods, our cost estimates can serve as
benchmarks for episode-driven payments.
Second, this study found that ICI use is associated with higher average healthcare
expenditures among older Medicare beneficiaries with late-stage melanoma. This is the first
study to the best of our knowledge to assess the association of ICI use on healthcare expenditures
among older adults with late-stage melanoma. Despite having similar expenditures during the
pre-index periods (t1, t2, and t3), use of ICI significantly increased post-index date (t4, t5, and t6)
expenditures. As seen in our study, outpatient expenditures were the major drivers of healthcare
expenditures, contributing to 83% of the total expenditures. This study also found that ICI use
was not associated with inpatient expenditures. Taken together these findings suggest that
healthcare costs of ICI users may be driven by supportive care. Reasons for these findings are
speculated as follows. It is reported that administration costs associated with ICIs are higher
compared to other therapies.15 Intravenous infusion of ICI requires constant monitoring by a
healthcare professional, which may lead to higher healthcare utilization.46 Infusion reactions or
immune-related adverse events may occur thereby increasing healthcare resource utilization.46
Another possible reason could be the constant monitoring and testing of patients in the outpatient
settings being treated with ICI.46 Prior to and after infusion, late-stage melanoma patients are
usually tested for serum biomarkers, enzyme level, and blood count.46 The study findings
confirm that cancer-related treatments have shifted from inpatient to outpatient settings.45,47
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Third, older Medicare beneficiaries with multimorbidity had higher average total
expenditures compared to those without multimorbidity. Across a range of healthcare settings
and population, disproportionately higher costs were accounted for in a small number of patients
and multimorbidity was highly prevalent in those patients.48 A majority of older adults with latestage melanoma also had multimorbidity.38 Therefore, higher total expenditures among older
adults with multimorbidity corroborates findings from other studies.6,36 Many alternatives to
traditional healthcare practices and payment models are being considered to account for the
complex need of patients with multimorbidity.35 Accountable Care Organizations and patientcentered medical homes over traditional practice models and bundled payment of services, which
is more patient-centric than disease-centric, are a few such efforts.35 Though there are numerous
challenges to adopting such policies on a larger scale,35 future studies need to explore whether
these emerging models are effective in providing value-based care at lower costs for cancer
patients in general and late-stage cancer patients in particular.
Fourth, the ICI-multimorbidity interaction revealed that multimorbidity did not play a
significant role in the increase of expenditures. Rather, the high expenditures were due to the use
of ICI. Although multimorbidity was associated with higher average expenditures in this study,
the expenditures due to ICI use supersede those expenditures. The possible reasons for the
increased average expenditures with ICI use are discussed above. These results further
strengthen the need for newer payment models such as OCM, which focus on reducing cost of
cancer care.
4.6. Strengths and Limitations
The findings of this study should be interpreted considering its limitations. First, Part D
costs were not included. This is because patients with multimorbidity will have higher
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prescription costs compared to those without multimorbidity. This may show even higher costs
for patients with multimorbidity, which would be unrelated to cancer care. However, the current
therapies for melanoma are covered under Part B. Therefore, melanoma-related treatment costs
were adequately captured in this study. Second, information on severity of co-existing illnesses
may have provided insights into cluster of conditions which may lead to higher healthcare
expenditures. Third, the findings of this study cannot be generalized to all Medicare
beneficiaries as the study population was limited to only those residing in SEER regions. Fourth,
a 12-month follow-up period may not be adequately assessing the impact of various factors on
healthcare expenditures. However, the mean overall survival for late-stage melanoma is
approximately a year. Therefore, a 12-month follow-up period was chosen. Despite these
limitations, the study has several strengths. This study adopted a longitudinal design and
compared expenditures over time. Additionally, no study to-date has focused on impact of ICI
on healthcare expenditures among older adults with multimorbidity and late-stage melanoma.
This study provides payers with strong evidence on the influences of various factors on
healthcare expenditures.
4.7. Conclusion
The results of this study illustrate that the healthcare expenditures were higher after a
late-stage melanoma diagnosis. Use of ICIs and presence of multimorbidity were associated
with higher expenditures. Outpatient expenditures contributed largely to the increase in total
expenditures. However, the ICI-multimorbidity interaction revealed that ICI was the driving
force behind the higher expenditures. Future studies are needed to explore healthcare utilization
among older patients with multimorbidity and late-stage melanoma and explore its effect on
healthcare expenditures.

55

FIGURE
Figure 4.1: Schematic of the study design. Each individual was observed for 24 months with a
12-month pre-index and 12-month post-index period. Healthcare expenditures and selected
independent variables were measured repeatedly every 120 days during the pre-index (t1, t2, and
t3) and post-index (t4, t5, and t6) periods, yielding a total of six repeated measures for every
individual.

56

FIGURE
Figure 4.2: (a) Mean Total and Type of Healthcare Expenditures Over time; (b) Mean Total Healthcare Expenditures by ICI user
status
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Based on 6 repeated observation of 4,519 older adults with incident late-stage (Stage III/IV) melanoma continuously enrolled in Medicare Parts A
and B fee-for-service programs 12 months prior to incident cancer diagnosis.
Abbreviations: HHA, Home health care; ICI, Immune checkpoint inhibitors; USD, United States Dollars
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FIGURE

Mean total expenditure 2016 USD

Figure 4.3: Mean total healthcare expenditures by ICI-Multimorbidity groups during pre-index
and post-index periods
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TABLES
Table 4.1: Parameter estimates of select variables of GLMM on average total healthcare
expenditures
No Interaction
With interaction
Variables
Unadjusted analysis
Beta
SE
Prob
Beta
SE
Prob
Time
0.83
0.04
<0.001
0.83
0.04
<0.001
ICI use
N/A
Yes
1.34
0.52
<0.001
No
(ref)
Multimorbidity
N/A
Yes
0.96
0.74
<0.001
No
(ref)
ICI-Multimorbidity Interaction
N/A
Yes ICI and Yes Multimorbidity
0.19
0.10
0.051
Yes ICI and No Multimorbidity
(ref)
No ICI and Yes Multimorbidity
-0.97
0.09
<0.001
No ICI and No Multimorbidity
-1.99
0.12
<0.001
Time squared
-0.15
0.01
<0.001
-0.15
0.01
<0.001
No Interaction
With interaction
Fully adjusted analysis╪
Beta
SE
Prob
Beta
SE
Prob
Time
0.49
0.04
<0.001
0.50
0.04
<0.001
ICI use
N/A
Yes
0.91
0.07
<0.001
No
(ref)
Multimorbidity
N/A
Yes
0.72
0.07
<0.001
No
(ref)
ICI-Multimorbidity Interaction
N/A
Yes ICI and Yes Multimorbidity
0.02
0.16
0.90
Yes ICI and No Multimorbidity
((ref)
No ICI and Yes Multimorbidity
-0.73
0.14
<0.001
No ICI and No Multimorbidity
-1.51
0.15
<0.001
Time squared
-0.12
0.01
<0.001
-0.12
0.01
<0.001
Note: Based on 6 repeated observation of 4,519 older adults with incident late-stage (Stage III/IV)
melanoma continuously enrolled in Medicare Parts A and B fee-for-service programs 12 months prior to
incident cancer diagnosis.
╪
Fully adjusted model also included year of diagnosis, age, sex, race, marital status, dual eligibility,
oncologist visit, and primary care physician visits.
Probability p<0.05 was considered significant
Abbreviations: GLMM, Generalized linear mixed model; ICI, Immune checkpoint inhibitors; N/A, Not
applicable; Prob, Probability; ref, Reference; SE, Standard error
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CHAPTER 5
5. SUMMARY AND CONCLUSION
5.1. Summary of Findings and Discussion
Pre-existing multimorbidity is prevalent among the elderly yet remains
understudied among older patients with melanoma. Patients with cancer often present with
multiple chronic conditions, i.e. multimorbidity.65,66 Cancer is usually a manifestation of adverse
lifestyles, such as smoking, obesity, and alcohol use, which are also the underlying causes of
other chronic conditions.77 Therefore, as a person ages, they accumulate chronic conditions,
thereby increasing the prevalence of multimorbidity in older ages, especially among the elderly
(>65 years) patients with cancer.148 Despite being rampant in patients with cancer,
multimorbidity is not included in cancer care. This is because patients with multimorbidity are
often excluded from randomized clinical trials (RCTs).72 Moreover, guidelines often adopt a
“single-disease” approach, thereby posing a problem to oncologists on treating such patients.72
Information on prevalence of pre-existing multimorbidity may shed light on the need to update
guidelines to include multimorbidity in cancer care.
While prevalence of multimorbidity in other cancers has been studied in detail, late-stage
melanoma has not received wide attention. This may be because late-stage melanoma is the
deadliest form of skin cancer with a high mortality rate.24 However, this was also the first cancer
for which immune checkpoint inhibitors (ICI) were approved for treatment.92 The clinical trials
of ICIs reported a significant improvement in the mean overall survival of patients with latestage melanoma, increasing from six to eight months to up to five years.93,149,150 As survivors of
late-stage melanoma may increase, knowledge on the prevalence of pre-existing multimorbidity
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will assist healthcare providers personalize care for their older patients by creating guidelines
with chronic conditions in mind.
Prevalence of pre-existing multimorbidity among older adults with late-stage
melanoma is high. This is the first study to explore the prevalence and factors associated with
the presence and type of multimorbidity among older adults with late-stage melanoma in the US.
This study found that pre-existing multimorbidity is highly prevalent among older adults with
four out of five patients having two or more chronic conditions. This study also notes that the
most common comorbid conditions were cardiovascular, endocrine, and musculoskeletal
diseases or a combination of the three in dyads and triads. Cardiovascular, endocrine, and
musculoskeletal diseases are highly prevalent in older adults.75,76 As these diseases and cancer
share modifiable risk factors, with some studies stating a bidirectional relationship between
them, our findings were not surprising.77–79 These findings point to the fact that healthcare
providers managing patients with late-stage melanoma may need to routinely monitor for the
presence of these conditions and coordinate their care with the primary care physicians.
Various types of multimorbidity (any, physical health conditions [PHC], autoimmune
diseases [AD], and mental health conditions [MHC] multimorbidity) and the risk factors
associated with those multimorbidity were also explored. This study confirms findings from
previous studies that age is a risk-factor for any multimorbidity.29,33 The region of residence was
also associated with multimorbidity; however, studies on regional variations are lacking for us to
adequately explain these results. The PHC multimorbidity shared risk-factors with any
multimorbidity, perhaps because PHC contributed to the bulk of multimorbidity. Pre-existing
AD was one of the PHC focused on, because of its complicated relationship with ICIs and the
surge of interest in this condition among the oncology community. This study found that
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although prevalence of pre-existing AD was not high, one in 10 older patients with late-stage
melanoma will present with multimorbidity. Moreover, sex, region, and social support as a risk
factor for AD multimorbidity also mimicked the findings of a previous studies.36,82,83
Oncologists should consider these risk factors when deciding if a drug acting via the immune
system (such as ICI) is the best course of treatment for older patients. About 30% of older adults
with late-stage melanoma in this study were diagnosed with any MHC, consistent with
literature.84,85 The risk factors associated with MHC were sex, social support, and dual
Medicare/Medicaid eligibility, which was consistent with previous studies.86–90 These risk
factors with MHC should be assessed in order to reduce further psychological distress and
appropriate follow-up interventions.
The treatment landscape of late-stage melanoma has changed since the approval of
ICIs in 2011. However, it is unknown if these changes have been implemented to realworld clinical settings. Despite the poor prognosis for survival, an overwhelming majority
(82%) of older patients in this study did not receive any treatment for their late-stage melanoma,
which was consistent with a previous study on chemotherapy for late-stage melanoma
treatment.101 In addition, the rates of treatment with ICI in the study was very low (6%) and
lower than that reported in recent studies.25,102,103 The reason speculated was due to the
differences in the population studied. The study also focused on older adults with 85% having
pre-existing multimorbidity who may be at high risk for poor survival prognosis. As evidence is
still emerging on the side effect profile of ICIs compared to existing modalities,104 oncologists
may be cautious in using ICI among older patients with late-stage melanoma.
The factors associated with use of ICI among older patients with late-stage melanoma
were determined to be lower age range, presence of social support in the form of a spouse,
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having dual Medicare/Medicaid eligibility, residing in Northeast region, and recent years of
diagnosis. However, multimorbidity was not significantly associated with receipt of ICI
suggesting that multimorbidity was not a barrier in the receipt of ICI. Since guidelines on cancer
care do not take multimorbidity into consideration, these results entail that those lack of
guidelines may force oncologists to use newer therapies despite concerns regarding additional
conditions.
Healthcare expenditures in the United States are increasing. However, healthcare
expenditures associated with ICI use and multimorbidity among older-adults with latestage melanoma remain unknown. This study reports that healthcare expenditures
significantly increased after a terminal cancer, such as late-stage melanoma, diagnosis, which is
in line with published studies.50–52,127 Older patients who had multimorbidity and those who had
used ICI had significantly higher healthcare expenditures compared to those who did not have
multimorbidity and had not use ICIs. Moreover, among ICI users, outpatient expenditures were
the driving force behind total expenditures, accounting for 83% of the total expenditures. This
confirmed findings from previous studies that late-stage melanoma care have shifted from
inpatient to outpatient settings.54,147 In addition, the administration costs associated with ICIs are
higher compared to other therapies.130 The ICI-multimorbidity interaction revealed that
irrespective of the multimorbidity status, ICI was the driving force behind the total healthcare
expenditures. This finding shows that expenditures associated with ICI use were higher than
those accrued by multimorbidity. Taken together, the use of ICI is significantly associated with
higher total healthcare expenditures.
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5.2. Implications and suggestions for future research
The findings of this study suggest that oncologists will encounter four in five older latestage melanoma patients with multimorbidity. With lack of late-stage melanoma treatment
guidelines for older patients with multimorbidity, clinicians and other stakeholders should
consider updating guidelines to better guide healthcare workers on treatment of such patients.
The lack of clear evidence from clinical trials and guidelines may, therefore, leave oncologists
guessing on treating older patients with newer therapies. With an already poor prognosis
associated with late-stage melanoma, ICIs may be used regardless of multimorbidity.
Future studies exploring the outcomes, such as . overall survival, associated with ICI use
for late-stage melanoma in older adults with multimorbidity may shed light on the effectiveness
of ICI in this subpopulation. Further, exploring the effect of various dyad and triad clusters of
chronic conditions on survival after ICI use may provide useful information on conditions highly
susceptible to adverse outcomes after ICI use. For example, patients with pre-existing
autoimmune diseases and cardiovascular diseases may not be good candidates for receiving ICI
compared to patients with osteoporosis and depression. This is because conditions like
cardiovascular diseases have intersecting pathways with cancer, as explained above, and
therefore, are adversely affected by ICI further exacerbating these conditions. Health-related
quality of life among ICI users and nonusers was not explored in this study. Future studies can
explore the humanistic burden of ICI use among older adults with or without multimorbidity.
Healthcare expenditures were higher among ICI users, regardless of multimorbidity. The
newer payment models like Oncology Care Models are needed now more than ever to reduce
healthcare expenditures. This study provides policymakers, healthcare workers, and other
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stakeholders with a starting point for curbing the high expenditures among older patients with
late-stage melanoma.
Future studies can further explore the healthcare utilization among these patients and the
difference in healthcare expenditures between ICI users and non-users. Moreover, future studies
can also include Part D expenditures. Prescription drug expenditures may be higher among
patients with multimorbidity compared to those without multimorbidity. Therefore, the
healthcare expenditures of older patients with multimorbidity may be even higher. These studies
will strengthen the need for preventative measures to avoid multimorbidity among the elderly.
5.3. Strengths and Limitations
The present study has several limitations. First, SEER does not contain information on
individual behavior such as smoking status, alcohol consumption, or functional status, all of
which can further affect the risk of having multimorbidity. Second, individual-level
socioeconomic factors, such as education and income were not available. Third, information on
severity of co-existing illnesses may have provided insights into whether the intake is low
because of competing demands that may confer high mortality risk and may have precluded the
use of ICI. Fourth, the reasons for not receiving any treatment in older patients was unknown.
Though disparities in ICI use were observed, the reason for these disparities, whether due to
patient preferences or shared decision-making of providers and patients, could not be evaluated.
Such information could direct healthcare providers on measures that can be taken to enhance the
adoption of ICIs. Fifth, the database did not have detailed information on tumor characteristics
or genetic markers such as BRAF status. Information on these could provide further insights into
use of ICIs. Sixth, Part D medications were unavailable to us and therefore, prescription
expenditure was not included. However, the current therapies for melanoma are covered under
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Part B. Therefore, melanoma-related treatment costs were adequately captured in this study.
Seventh, a 12-month follow-up period may not be adequately assessing the impact of various
factors on healthcare expenditures. However, the mean overall survival for late-stage melanoma
is approximately a year. Therefore, a 12-month follow-up period was chosen.
Despite these limitations, this study has several strengths. Although few studies on
comorbid conditions in individuals with melanoma exist, they did not focus on late-stage
melanoma, perhaps because the prognosis was poor with low chances of survival.91 Therefore,
prognostic burden of multimorbidity in such individuals was deemed less important.91 However,
newer therapies such as ICIs will improve survivorship of patients with late-stage melanoma.
Therefore, information on the prevalence and type of multimorbidity in such individuals can help
both physicians and patients in choice of cancer treatment, survivorship plans, and quality of life
care. An exhaustive list of PHC and MHC, including pre-existing AD was included. Moreover,
no study to-date has focused on treatment of older adults with multimorbidity and late-stage
melanoma. With a high prevalence, oncologists are bound to encounter such patients on a daily
basis. This study provides oncologists with strong evidence on the current treatment landscape
among older adults with multimorbidity. In addition, this study examined the factors associated
with ICI use. In the era of personalized medicines, patient-level factors play a critical role in
treatment decisions. This study sheds light on various factors that will help healthcare providers
in reaching a successful treatment goal with their older patients. The study on healthcare
expenditure adopted a longitudinal design and compared expenditures over time. The
longitudinal design allowed us to minutely look at the various time points pre- and post- cancer
diagnosis and evaluated the reasons for changing expenditures in during each time point. This
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study provides payers with strong evidence on the influences of various factors on healthcare
expenditures.
5.4. Conclusion
This dissertation concludes that prevalence of multimorbidity among older adults with
late-stage melanoma is high. However, multimorbidity is not a barrier to access to ICIs.
Multimorbidity is associated with higher expenditures compared to no multimorbidity.
However, when the patients were treated with ICI, the healthcare expenditures increased
significantly and the presence or absence of multimorbidity did not change the results. Clinical
trials have shown that the ICIs have drastically improved survival of patients with late-stage
melanoma; however, they come with a hefty price tag. Future studies are needed to examine
overall survival among older patients with multimorbidity treated with ICIs to assess the riskbenefit of these newer therapies for late-stage melanoma.

67

6. REFERENCES
1.

Ward WH, Farma JM, eds. Cutaneous Melanoma: Etiology and Therapy. Brisbane (AU);
2017. doi:10.15586/codon.cutaneousmelanoma.2017

2.

Matthews NH, Li W-Q, Qureshi AA. Epidemiology of Melanoma. In: Ward W, Farma J,
eds. Cutaneous Melanoma: Etiology and Therapy [Internet]. Brisbane (AU): Codon
Publications; 2017. https://www.ncbi.nlm.nih.gov/books/NBK481862/ doi:
10.15586/codon.cutaneousmelanoma.2017.ch1.

3.

Tuong W, Cheng LS, Armstrong AW. Melanoma: Epidemiology, Diagnosis, Treatment,
and Outcomes. Dermatol Clin. 2012;30(1):113-124. doi:10.1016/j.det.2011.08.006

4.

National Cancer Institute. Bethesda M. SEER Cancer Stat Facts: Melanoma of the Skin.
SEER Cancer Statistics Review, 1975-2015.
https://seer.cancer.gov/statfacts/html/melan.html. Published 2018. Accessed May 15,
2019.

5.

ACS. Key Statistics for Melanoma Skin Cancer.
https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html. Accessed
April 6, 2020.

6.

Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview.
Oncology (Williston Park). 2009;23(6):488-496.
http://www.ncbi.nlm.nih.gov/pubmed/19544689%0Ahttp://www.pubmedcentral.nih.gov/a
rticlerender.fcgi?artid=PMC2737459.

7.

Gadeliya Goodson A, Grossman D. Strategies for early melanoma detection: Approaches
to the patient with nevi. J Am Acad Dermatol. 2009. doi:10.1016/j.jaad.2008.10.065

8.

Filippi AR, Fava P, Badellino S, Astrua C, Ricardi U, Quaglino P. Radiotherapy and

68

immune checkpoints inhibitors for advanced melanoma. Radiother Oncol. 2016.
doi:10.1016/j.radonc.2016.06.003
9.

Song X, Zhao Z, Barber B, Farr AM, Ivanov B, Novich M. Overall survival in patients
with metastatic melanoma. Curr Med Res Opin. 2015.
doi:10.1185/03007995.2015.1021904

10.

Karimkhani C, Green AC, Nijsten T, et al. The global burden of melanoma: results from
the Global Burden of Disease Study 2015. Br J Dermatol. 2017;177(1):134-140.
doi:10.1111/bjd.15510

11.

Chang CK, Jacobs IA, Vizgirda VM, Salti GI. Melanoma in the elderly patient. Arch Surg.
2003. doi:10.1001/archsurg.138.10.1135

12.

Tas F, Erturk K. Patient age and cutaneous malignant melanoma: Elderly patients are
likely to have more aggressive histological features and poorer survival. Mol Clin Oncol.
2017. doi:10.3892/mco.2017.1439

13.

Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for
metastatic melanoma: Synthesis of evidence from randomized trials. Cancer Treat Rev.
2007;33(8):665-680. doi:10.1016/j.ctrv.2007.06.004

14.

Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: An overview.
Oncology. 2009.

15.

Rao RD, Holtan SG, Ingle JN, et al. Combination of and paclitaxel and carboplatin as
second-line therapy for patients with metastatic melanoma. Cancer. 2006;106(2):375-382.
doi:10.1002/cncr.21611

16.

Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined
chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy

69

using interleukin-2 and interferon-. Ann Oncol. 1996.
doi:10.1093/oxfordjournals.annonc.a010762
17.

Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common
denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450-461.
doi:10.1016/j.ccell.2015.03.001

18.

Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade
therapy. Cancer Discov. 2018;8(9):1069-1086. doi:10.1158/2159-8290.CD-18-0367

19.

Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged Survival in Stage III
Melanoma with Ipilimumab Adjuvant Therapy. N Engl J Med. 2016;375(19):1845-1855.
doi:10.1056/NEJMoa1611299

20.

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or
Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23-34.
doi:10.1056/NEJMoa1504030

21.

Robert C, Schachter J, Long G V, et al. Pembrolizumab versus Ipilimumab in Advanced
Melanoma. N Engl J Med. 2015;372(26):2521-2532. doi:10.1056/NEJMoa1503093

22.

Robert C, Long G V., Schachter J, et al. Long-term outcomes in patients (pts) with
ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who
completed pembrolizumab (pembro) treatment. J Clin Oncol. 2018;35(15_suppl):95049504. doi:10.1200/jco.2017.35.15_suppl.9504

23.

Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab
alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes
of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480-1492.
doi:10.1016/S1470-2045(18)30700-9

70

24.

Lewis MG. Melanoma. 1st ed. (Kaufman HL, Mehnert JM, eds.). Springer International
Publishing; 2011. doi:10.1007/978-3-642-80725-1_9

25.

Liu FX, Ou W, Diede SJ, Whitman ED. Real-world experience with pembrolizumab in
patients with advanced melanoma. Medicine (Baltimore). 2019.
doi:10.1097/md.0000000000016542

26.

WHO. Multimorbidity. Technical Series on Safer Primary Care. World Heal Organ. 2016.
doi:10.1097/01.NURSE.0000524761.58624.1f

27.

Pache B, Vollenweider P, Waeber G, Marques-Vidal P. Prevalence of measured and
reported multimorbidity in a representative sample of the Swiss population Disease
epidemiology - Chronic. BMC Public Health. 2015. doi:10.1186/s12889-015-1515-x

28.

Sambamoorthi U, Tan X, Deb A. Multiple chronic conditions and healthcare costs among
adults. Expert Rev Pharmacoeconomics Outcomes Res. 2015.
doi:10.1586/14737167.2015.1091730

29.

Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013.
doi:10.1093/epirev/mxs009

30.

Yarnall AJ, Sayer AA, Clegg A, Rockwood K, Parker S, Hindle J V. New horizons in
multimorbidity in older adults. Age Ageing. 2017. doi:10.1093/ageing/afx150

31.

Buja A, Claus M, Perin L, et al. Multimorbidity patterns in high-need, high-cost elderly
patients. PLoS One. 2018. doi:10.1371/journal.pone.0208875

32.

Bebe FN, Hu S, Brown TL, Tulp OL. Role, extent, and impact of comorbidity on
prognosis and survival in advanced metastatic melanoma: A review. J Clin Aesthet
Dermatol. 2019.

33.

Grann AF, Frøslev T, Olesen AB, Schmidt H, Lash TL. The impact of comorbidity and

71

stage on prognosis of Danish melanoma patients, 1987-2009: A registry-based cohort
study. Br J Cancer. 2013. doi:10.1038/bjc.2013.246
34.

Schubert-Fritschle G, Schlesinger-Raab A, Hein R, et al. Quality of life and comorbidity
in localized malignant melanoma: Results of a German population-based cohort study. Int
J Dermatol. 2013. doi:10.1111/j.1365-4632.2011.05401.x

35.

Peddi P, Oh JH, Kim KB, et al. Impact of comorbidities on overall survival of high-risk
and advanced melanoma. ASCO Meet Abstr . 2012;30(15_suppl):8536.
doi:10.1200/jco.2012.30.15_suppl.8536

36.

Ma Q, Shilkrut M, Zhao Z, Li M, Batty N, Barber B. Autoimmune comorbidities in
patients with metastatic melanoma: A retrospective analysis of us claims data. BMC
Cancer. 2018. doi:10.1186/s12885-018-4051-0

37.

Niedzwiedz CL, Knifton L, Robb KA, Katikireddi SV, Smith DJ. Depression and anxiety
among people living with and beyond cancer: A growing clinical and research priority.
BMC Cancer. 2019. doi:10.1186/s12885-019-6181-4

38.

Park EM, Gelber S, Rosenberg SM, et al. Anxiety and Depression in Young Women With
Metastatic Breast Cancer: A Cross-Sectional Study. Psychosomatics. 2018.
doi:10.1016/j.psym.2018.01.007

39.

Peng YN, Huang ML, Kao CH. Prevalence of depression and anxiety in colorectal cancer
patients: A literature review. Int J Environ Res Public Health. 2019.
doi:10.3390/ijerph16030411

40.

Watts S, Leydon G, Birch B, et al. Depression and anxiety in prostate cancer: A
systematic review and meta-analysis of prevalence rates. BMJ Open. 2014.
doi:10.1136/bmjopen-2013-003901

72

41.

Baillargeon J, Kuo YF, Lin YL, Raji MA, Singh A, Goodwin JS. Effect of mental
disorders on diagnosis, treatment, and survival of older adults with colon cancer. J Am
Geriatr Soc. 2011. doi:10.1111/j.1532-5415.2011.03481.x

42.

Danlos FX, Voisin AL, Dyevre V, et al. Safety and efficacy of anti-programmed death 1
antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
Eur J Cancer. 2018. doi:10.1016/j.ejca.2017.12.008

43.

Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with
advanced melanoma and preexisting autoimmune disorders or major toxicity with
ipilimumab. Ann Oncol. 2017. doi:10.1093/annonc/mdw443

44.

Snyder CF, Frick KD, Herbert RJ, et al. Comorbid condition care quality in cancer
survivors: role of primary care and specialty providers and care coordination. J Cancer
Surviv. 2015. doi:10.1007/s11764-015-0440-4

45.

Garg R, Sambamoorthi U, Tan X, Basu SK, Haggerty T, Kelly KM. Impact of diffuse
large B-cell lymphoma on visits to different provider specialties among elderly Medicare
beneficiaries: Challenges for care coordination. Transl Behav Med. 2018.
doi:10.1093/tbm/ibx071

46.

Nipp R, Tramontano AC, Kong CY, et al. Disparities in cancer outcomes across age, sex,
and race/ethnicity among patients with pancreatic cancer. Cancer Med. 2018.
doi:10.1002/cam4.1277

47.

Datta GD, Neville BA, Kawachi I, Datta NS, Earle CC. Marital status and survival
following bladder cancer. J Epidemiol Community Health. 2009.
doi:10.1136/jech.2008.082438

48.

Krimphove MJ, Tully KH, Friedlander DF, et al. Adoption of immunotherapy in the

73

community for patients diagnosed with metastatic melanoma. J Immunother Cancer.
2019. doi:10.1186/s40425-019-0782-y
49.

Shih YCT, Elting LS, Halpern MT. Factors associated with immunotherapy use among
newly diagnosed cancer patients. Med Care. 2009. doi:10.1097/MLR.0b013e31819a5b2b

50.

Guy GP, Ekwueme DU, Yabroff KR, et al. Economic burden of cancer survivorship
among adults in the United States. J Clin Oncol. 2013. doi:10.1200/JCO.2013.49.1241

51.

De Oliveira C, Pataky R, Bremner KE, et al. Estimating the cost of cancer care in British
Columbia and Ontario: A Canadian inter-provincial comparison. Healthc Policy. 2017.
doi:10.12927/hcpol.2017.25024

52.

Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the
United States. J Natl Cancer Inst. 2008. doi:10.1093/jnci/djn103

53.

Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous
melanoma. J Am Acad Dermatol. 1998;38(5 I):669-680. doi:10.1016/S01909622(98)70195-1

54.

Guy GP, Ekwueme DU, Tangka FK, Richardson LC. Melanoma treatment costs: A
systematic review of the literature, 1990-2011. Am J Prev Med. 2012.
doi:10.1016/j.amepre.2012.07.031

55.

Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC. Economic Burden of Melanoma
in the Elderly Population. Arch Dermatol. 2010. doi:10.1001/archdermatol.2009.389

56.

Dranitsaris G, Zhu X, Adunlin G, Vincent MD. Cost effectiveness vs. affordability in the
age of immuno-oncology cancer drugs. Expert Rev Pharmacoeconomics Outcomes Res.
2018. doi:10.1080/14737167.2018.1467270

57.

Andrews A. Treating with Checkpoint Inhibitors-Figure $1 Million per Patient. Am Heal

74

drug benefits. 2015.
58.

Ghate SR, Ionescu-Ittu R, Burne R, et al. Healthcare resource utilization in patients with
metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus
nivolumab or pembrolizumab monotherapy. Curr Med Res Opin. 2018.
doi:10.1080/03007995.2018.1501351

59.

Zulman DM, Chee CP, Wagner TH, et al. Multimorbidity and healthcare utilisation
among high-cost patients in the US Veterans Affairs Health Care System. BMJ Open.
2015. doi:10.1136/bmjopen-2015-007771

60.

Wilkinson R, Marmot M. Determinants of Health. The Solid Facts. 2nd Edition. World
Heal Organiztaion. 2003. doi:10.1016/j.jana.2012.03.001

61.

Phillips KA, Morrison KR, Andersen R, Aday LA. Understanding the context of
healthcare utilization: assessing environmental and provider-related variables in the
behavioral model of utilization. Health Serv Res. 1998.

62.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):734. doi:10.3322/caac.21551

63.

Glazer AM, Winkelmann RR, Farberg AS, Rigel DS. Analysis of trends in US melanoma
incidence and mortality. JAMA Dermatology. 2017. doi:10.1001/jamadermatol.2016.4512

64.

Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment.
CA Cancer J Clin. 2016;66(4):337-350. doi:10.3322/caac.21342

65.

Kenzik K, Richman J, Kent EE, Pisu M, Bhatia S. Impact of precancer multimorbidity
clusters on survival and functional outcomes after cancer in older patients. J Clin Oncol.
2016. doi:10.1200/jco.2016.34.7_suppl.291

66.

Meneses K, Benz R, Azuero A, Jablonski-Jaudon R, McNees P. Multimorbidity and

75

breast cancer. Semin Oncol Nurs. 2015. doi:10.1016/j.soncn.2015.02.004
67.

Georgieva M, Lund J, Nielsen M, et al. The Impact of Functional Status and MultiMorbidity On Surveillance Use Among Medicare Beneficiaries with Bladder Cancer.
Value Heal. 2018. doi:10.1016/j.jval.2018.04.951

68.

LUQUE-FERNANDEZ MA, Redondo-Sanchez D, RODRIGUEZ-BARRANCO M,
Garcia MCC, Marcos-Gragera R, SANCHEZ-PEREZ MJ. The pattern of Comorbidities
and Associated Risk Factors among Colorectal Cancer Patients in Spain: CoMCoR study.
bioRxiv. 2019. doi:10.1101/526673

69.

Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic Review of
Medical Treatment in Melanoma: Current Status and Future Prospects. Oncologist. 2011.
doi:10.1634/theoncologist.2010-0190

70.

Shrestha A, Martin C, Burton M, Walters S, Collins K, Wyld L. Quality of life versus
length of life considerations in cancer patients: A systematic literature review.
Psychooncology. 2019. doi:10.1002/pon.5054

71.

Gutzmer R, Koop A, Meier F, et al. Programmed cell death protein-1 (PD-1) inhibitor
therapy in patients with advanced melanoma and preexisting autoimmunity or
ipilimumab-triggered autoimmunity. Eur J Cancer. 2017. doi:10.1016/j.ejca.2016.12.038

72.

Donia M, Kimper-Karl ML, Høyer KL, Bastholt L, Schmidt H, Svane IM. The majority of
patients with metastatic melanoma are not represented in pivotal phase III immunotherapy
trials. Eur J Cancer. 2017. doi:10.1016/j.ejca.2016.12.017

73.

Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and measuring
chronic conditions: Imperatives for research, policy, program, and practice. Prev Chronic
Dis. 2013. doi:10.5888/pcd10.120239

76

74.

AARDA. Autoimmune Disease List. https://www.aarda.org/diseaselist/. Published 2019.

75.

Halter JB, Musi N, Horne FMF, et al. Diabetes and cardiovascular disease in older adults:
Current status and future directions. Diabetes. 2014. doi:10.2337/db14-0020

76.

Williams A, Kamper SJ, Wiggers JH, et al. Musculoskeletal conditions may increase the
risk of chronic disease: A systematic review and meta-analysis of cohort studies. BMC
Med. 2018. doi:10.1186/s12916-018-1151-2

77.

Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular
disease and cancer. Circulation. 2016. doi:10.1161/CIRCULATIONAHA.115.020406

78.

Vincent L, Leedy D, Masri SC, Cheng RK. Cardiovascular Disease and Cancer: Is There
Increasing Overlap? Curr Oncol Rep. 2019. doi:10.1007/s11912-019-0796-0

79.

Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: A consensus report.
In: Diabetes Care. ; 2010. doi:10.2337/dc10-0666

80.

Ferrucci L, Giallauria F, Guralnik JM. Epidemiology of Aging. Radiol Clin North Am.
2008. doi:10.1016/j.rcl.2008.07.005

81.

Gurney J, Sarfati D, Stanley J. The impact of patient comorbidity on cancer stage at
diagnosis. Br J Cancer. 2015;113(9):1375-1380. doi:10.1038/bjc.2015.355

82.

Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a
pathological perspective. Am J Pathol. 2008. doi:10.2353/ajpath.2008.071008

83.

Carpenter DM, Thorpe CT, Alexander DS, et al. The Relationship Between Social
Support, Social Constraint, and Psychological Adjustment for Patients with Rare
Autoimmune Disease. Curr Rheumatol Rev. 2016.
doi:10.2174/1573397112666160719163145

84.

Kasparian NA. Psychological stress and melanoma: Are we meeting our patients’

77

psychological needs? Clin Dermatol. 2013. doi:10.1016/j.clindermatol.2011.11.005
85.

Kasparian NA, McLoone JK, Butow PN. Psychological responses and coping strategies
among patients with malignant melanoma: A systematic review of the literature. Arch
Dermatol. 2009. doi:10.1001/archdermatol.2009.308

86.

Kasparian NA, Meiser B, Butow PN, Simpson JM, Mann GJ. Predictors of psychological
distress among individuals with a strong family history of malignant melanoma. Clin
Genet. 2008. doi:10.1111/j.1399-0004.2007.00949.x

87.

Anuk D, Özkan M, Kizir A, Özkan S. The characteristics and risk factors for common
psychiatric disorders in patients with cancer seeking help for mental health. BMC
Psychiatry. 2019. doi:10.1186/s12888-019-2251-z

88.

Pitman A, Suleman S, Hyde N, Hodgkiss A. Depression and anxiety in patients with
cancer. BMJ. 2018. doi:10.1136/bmj.k1415

89.

Hung C-T, Chen Y-J, Chan J-C, et al. Psychological distress, social support, selfmanagement ability and utilization of social resources for female patients with cancer in
Oncology Outpatient Settings in Taiwan. Support Care Cancer. 2019;[Epub ahea.
doi:10.1007/s00520-019-05143-y

90.

Amini A, Rusthoven CG, Waxweiler T V., et al. Association of health insurance with
outcomes in adults ages 18 to 64 years with melanoma in the United States. J Am Acad
Dermatol. 2016. doi:10.1016/j.jaad.2015.09.054

91.

Read WL, Tierney RM, Page NC, et al. Differential prognostic impact of comorbidity. J
Clin Oncol. 2004. doi:10.1200/JCO.2004.08.040

92.

Kaufman HL, Margolin K, Sullivan R. Management of Metastatic Melanoma in 2018.
JAMA Oncol. 2018;4(6):857. doi:10.1001/jamaoncol.2018.0170

78

93.

Eggermont AMM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo
after complete resection of high-risk stage III melanoma (EORTC 18071): A randomised,
double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522-530. doi:10.1016/S14702045(15)70122-1

94.

Bennette CS, Torres AZ, Tucker M, et al. Diffusion of innovation in oncology: A case
study of immuno-oncology (IO) adoption for advanced non-small lung cancer (aNSCLC)
patients across practices in the US. J Clin Oncol. 2018;36(15_suppl):6537-6537.
doi:10.1200/JCO.2018.36.15_suppl.6537

95.

Cybulska-Stopa B, Ługowska I, Jagodzińska-Mucha P, et al. Immune checkpoint
inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre
study. Postep Dermatol Alergol. 2019;36(5):566-571. doi:10.5114/ada.2018.79940

96.

Ben-Betzalel G, Steinberg-Silman Y, Stoff R, et al. Immunotherapy comes of age in
octagenarian and nonagenarian metastatic melanoma patients. Eur J Cancer. 2019.
doi:10.1016/j.ejca.2018.12.012

97.

van Holstein Y, Kapiteijn E, Bastiaannet E, van den Bos F, Portielje J, de Glas NA.
Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older
Patients with Cancer. Drugs Aging. 2019;36(10):927-938. doi:10.1007/s40266-01900697-2

98.

Hegde UP, Parmar H V, Stevenson CE. Clinical heterogeneity of elderly melanoma
patients in the real-world setting: Potential implications for treatment outcomes following
immune based therapy. In: Journal of Clinical Oncology. Vol 37. ; 2019:e21026-e21026.
doi:0.1200/JCO.2019.37.15_suppl.e21026

99.

Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide

79

versus dacarbazine in the treatment of patients with advanced metastatic malignant
melanoma. J Clin Oncol. 2000. doi:10.1200/jco.2000.18.1.158
100. Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic
malignant melanoma. J Med Life. 2014.
101. Walker MS, Reyes C, Kerr J, Satram-Hoang S, Stepanski EJ. Treatment patterns and
outcomes among patients with metastatic melanoma treated in community practice. Int J
Dermatol. 2014. doi:10.1111/ijd.12427
102. Whitman ED, Liu FX, Cao X, Diede SJ, Haiderali A, Abernethy AP. Treatment patterns
and outcomes for patients with advanced melanoma in US oncology clinical practices.
Futur Oncol. 2019;15(5):459-471. doi:10.2217/fon-2018-0620
103. Cowey CL, Liu FX, Boyd M, Aguilar KM, Krepler C. Real-world treatment patterns and
clinical outcomes among patients with advanced melanoma. Medicine (Baltimore). 2019.
doi:10.1097/md.0000000000016328
104. Pavlick A, Weber J. Managing Checkpoint Inhibitor Symptoms and Toxicity for
Metastatic Melanoma. In: Cutaneous Melanoma. ; 2020. doi:10.1007/978-3-030-050702_60
105. Orloff M. Melanoma Immunotherapy in the Elderly. Curr Oncol Rep. 2018.
doi:10.1007/s11912-018-0656-3
106. Unger JM, Hershman DL, Fleury ME, Vaidya R. Association of Patient Comorbid
Conditions with Cancer Clinical Trial Participation. JAMA Oncol. 2019.
doi:10.1001/jamaoncol.2018.5953
107. Kent E, Mollica M, Klabunde CN, et al. Examining the relative influence of
multimorbidity on variations in older cancer patients’ experiences with care. J Clin Oncol.

80

2018. doi:10.1200/jco.2018.36.30_suppl.14
108. Garg R, Shen C, Sambamoorthi N, Kelly K, Sambamoorthi U. Type of Multimorbidity
and Patient-Doctor Communication and Trust among Elderly Medicare Beneficiaries. Int
J Family Med. 2016. doi:10.1155/2016/8747891
109. Given B, Given CW. Older adults and cancer treatment. In: Cancer. ; 2008.
doi:10.1002/cncr.23939
110. Shahrokni A, Wu AJ, Carter J, Lichtman SM. Long-term Toxicity of Cancer Treatment in
Older Patients. Clin Geriatr Med. 2016. doi:10.1016/j.cger.2015.08.005
111. Lai H, Lai S, Krongrad A, Trapido E, Page J, McCoy C. The effect of marital status on
survival in late-stage cancer patients: an analysis based on surveillance, epidemiology, and
end results (SEER) data, in the United States. Int J Behav Med. 1999;6(2):150-176.
doi:10.1207/s15327558ijbm0602_4
112. McLaughlin JM, Fisher JL, Paskett ED. Marital status and stage at diagnosis of cutaneous
melanoma: results from the Surveillance Epidemiology and End Results (SEER) program,
1973-2006. Cancer. 2011;117(9):1984-1993. doi:10.1002/cncr.25726
113. Walker JL. The Diffusion of Innovations among the American States. Am Polit Sci Rev.
1969. doi:10.2307/1954434
114. Carter LE, LaPlant JT. Diffusion of Health Care Policy Innovation in the United States.
State Local Gov Rev. 1997. doi:10.1177/0160323x9702900102
115. Agha L, Molitor D. The Local Influence of Pioneer Investigators on Technology
Adoption: Evidence from New Cancer Drugs. Rev Econ Stat. 2018.
doi:10.1162/rest_a_00670
116. Koroukian SM, Bakaki PM, Owusu C, Earle CC, Cooper GS. Cancer outcomes in low-

81

income elders: is there an advantage to being on Medicaid? Medicare Medicaid Res Rev.
2012. doi:10.5600/mmrr.002.02.a06
117. Lisa MH, Louder A, Winfree K, Zhu YE, Oton AB, Nair R. Factors associated with
adherence to and treatment duration of erlotinib among patients with non-small cell lung
cancer. J Manag Care Spec Pharm. 2017. doi:10.18553/jmcp.2017.16389
118. Al-Qurayshi Z, Crowther JE, Hamner JB, Ducoin C, Killackey MT, Kandil E. Disparities
of immunotherapy utilization in patients with stage III cutaneous melanoma: A national
perspective. Anticancer Res. 2018. doi:10.21873/anticanres.12536
119. Haque W, Verma V, Butler EB, Teh BS. Racial and Socioeconomic Disparities in the
Delivery of Immunotherapy for Metastatic Melanoma in the United States. J Immunother.
2019. doi:10.1097/CJI.0000000000000264
120. Verma V, Haque W, Cushman TR, et al. Racial and Insurance-related Disparities in
Delivery of Immunotherapy-type Compounds in the United States. J Immunother. 2019.
doi:10.1097/CJI.0000000000000253
121. Keating NL, O’Malley AJ, Onnela JP, Gray SW, Landon BE. Association of Physician
Peer Influence With Subsequent Physician Adoption and Use of Bevacizumab. JAMA
Netw open. 2020. doi:10.1001/jamanetworkopen.2019.18586
122. Ma X, Yu H. Global burden of cancer. Yale J Biol Med. 2006. doi:10.1016/s01406736(97)90017-9
123. Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden of Cancer 2013. JAMA Oncol.
2015. doi:10.1001/jamaoncol.2015.0735
124. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United
States: Estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev.

82

2011. doi:10.1158/1055-9965.EPI-11-0650
125. Davidoff AJ, Erten M, Shaffer T, et al. Out-of-pocket health care expenditure burden for
Medicare beneficiaries with cancer. Cancer. 2013. doi:10.1002/cncr.27848
126. Narang AK, Nicholas LH. Out-of-pocket spending and financial burden among medicare
beneficiaries with cancer. JAMA Oncol. 2017. doi:10.1001/jamaoncol.2016.4865
127. Park J, Look KA. Health Care Expenditure Burden of Cancer Care in the United States.
Inq (United States). 2019. doi:10.1177/0046958019880696
128. Chang CL, Schabert VF, Munakata J, et al. Comparative healthcare costs in patients with
metastatic melanoma in the USA. Melanoma Res. 2015.
doi:10.1097/CMR.0000000000000159
129. Oh A, Tran DM, Mc LCD, et al. Cost-effectiveness of nivolumab-ipilimumab
combination therapy compared with monotherapy for first-line treatment of metastatic
melanoma in the United States. J Manag Care Spec Pharm. 2017.
doi:10.18553/jmcp.2017.23.6.653
130. Toy EL, Vekeman F, Lewis MC, Oglesby AK, Duh MS. Costs, resource utilization, and
treatment patterns for patients with metastatic melanoma in a commercially insured
setting. Curr Med Res Opin. 2015. doi:10.1185/03007995.2015.1062356
131. Coughlin SS, Caplan L, Young L. A review of cancer outcomes among persons dually
enrolled in Medicare and Medicaid. J Hosp Manag Heal Policy. 2018.
doi:10.21037/jhmhp.2018.07.04
132. Shih YCT, Smieliauskas F, Geynisman DM, Kelly RJ, Smith TJ. Trends in the cost and
use of targeted cancer therapies for the privately insured nonelderly: 2001 To 2011. J Clin
Oncol. 2015. doi:10.1200/JCO.2014.58.2320

83

133. Jain V, Venigalla S, Reddy VK, Lukens JN, Mitchell TC, Shabason JE. Association of
Insurance Status with Presentation, Treatment, and Survival in Melanoma in the Era of
Immune Checkpoint Inhibitors. J Immunother. 2020. doi:10.1097/CJI.0000000000000294
134. Lohr KN. Medicare: a strategy for quality assurance. J Qual Assur. 1991.
doi:10.1111/j.1945-1474.1991.tb00115.x
135. Hegde UP, Grant-Kels JM. Metastatic melanoma in the older patient: Special
considerations. Clin Dermatol. 2013. doi:10.1016/j.clindermatol.2012.08.011
136. Kline RM, Bazell C, Smith E, Schumacher H, Rajkumar R, Conway PH. Centers for
Medicare and Medicaid Services: Using an Episode-Based Payment Model to Improve
Oncology Care. J Oncol Pract. 2015. doi:10.1200/jop.2014.002337
137. King DE, Xiang J, Pilkerton CS. Multimorbidity trends in United States adults, 1988–
2014. J Am Board Fam Med. 2018. doi:10.3122/jabfm.2018.04.180008
138. Lochner KA, Cox CS. Prevalence of multiple chronic conditions among medicare
beneficiaries, United States, 2010. Prev Chronic Dis. 2013. doi:10.5888/pcd10.120137
139. Schneider KM, O’Donnell BE, Dean D. Prevalence of multiple chronic conditions in the
United States’ Medicare population. Health Qual Life Outcomes. 2009. doi:10.1186/14777525-7-82
140. Wang L, Si L, Cocker F, Palmer AJ, Sanderson K. A Systematic Review of Cost-ofIllness Studies of Multimorbidity. Appl Health Econ Health Policy. 2018.
doi:10.1007/s40258-017-0346-6
141. Rim SH, Guy GP, Yabroff KR, McGraw KA, Ekwueme DU. The impact of chronic
conditions on the economic burden of cancer survivorship: a systematic review. Expert
Rev Pharmacoeconomics Outcomes Res. 2016. doi:10.1080/14737167.2016.1239533

84

142. Picco L, Achilla E, Abdin E, et al. Economic burden of multimorbidity among older
adults: Impact on healthcare and societal costs. BMC Health Serv Res. 2016.
doi:10.1186/s12913-016-1421-7
143. Rai P, Shen C, Kolodney J, Kelly K, Scott V, Sambamoorthi U. Prevalence and Risk
Factors for Multimorbidity in Elderly US Patients with Late-Stage Melanoma.; 2020.
144. Chopra I, Mattes MD, Findley P, Tan X, Dwibedi N, Sambamoorthi U. Impact of incident
cancer on short-term coronary artery disease–related healthcare expenditures among
Medicare beneficiaries. JNCCN J Natl Compr Cancer Netw. 2019.
doi:10.6004/jnccn.2018.7078
145. CPI. Bureau of Labor Statistics website. https://www.bls.gov/cpi/. Accessed February 24,
2020.
146. Manning WG, Mullahy J. Estimating log models: To transform or not to transform? J
Health Econ. 2001. doi:10.1016/S0167-6296(01)00086-8
147. Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA.
Cancer treatment cost in the United States: Has the burden shifted over time? Cancer.
2010. doi:10.1002/cncr.25150
148. Dudley N, Lee SJ, Stijacic-Cenzer I, Ritchie CS. Prevalence of Multimorbidity Among
Older Adults With Advanced Illness Visits to U.S. Subspecialty Clinics. J Pain Symptom
Manage. 2018. doi:10.1016/j.jpainsymman.2018.03.012
149. Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with
advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019.
doi:10.1093/annonc/mdz011
150. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients

85

with metastatic melanoma. N Engl J Med. 2010. doi:10.1056/NEJMoa1003466

86

7. APPENDIX
Appendix 7.1: List of autoimmune diseases
S.No.

Autoimmune disease

1

Achalasia

2

Addison's disease

3

Adult Still's disease

4

Agammaglobulinemia

5

Alopecia areata

6

Amyloidosis

7

Ankylosing spondylitis

8

Anti-GBM/Anti-TBM nephritis

9

Antiphospholipid syndrome

10

Autoimmune angioedema

11

Autoimmune dysautonomia

12

Autoimmune encephalomyelitis

13

Autoimmune heptatitis

14

Autoimmune inner ear disease (AIED)

15

Autoimmune myocarditis

16

Autoimmune oophoritis

17

Autoimmune orchitis

18

Autoimmune pancreatitis

19

Autoimmune retinopathy

20

Autoimmune urticaria

21

Axonal & neuronal neuropathy (AMAN)

22

Balo disease

23

Benign mucosal pemphigoid

24

Castleman disease

25

Celiac disease

27

Chagas disease

27

Chronic inflammatory demyelinating polyneuropathy (CIDP)

28

Chronic recurrent multifocal osteomyelitis (CRMO)

29

Cicatricial pemphigoid

30

Cogan's syndrome

31

Cold agglutinin disease

32

Congenital heart block

33

Coxsackie myocarditis

34

CREST syndrome

35

Crohn's disease

36

Dermatitis herpetiformis

37

Dermatomyositis

38

Devic's disease (neuromyelitis optica)
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S.No.

Autoimmune disease

39

Discoid lupus

40

Dressler's syndrome

41

Endometriosis

42

Eosinophilic esophagitis (EoE)

43

Eosinophilic fascitis

44

Erythema nodosum

45

Evan syndrome

46

Fibromyalgia

47

Fibrosing alveolitis

48

Giant cell myocarditis

49

Glomerulonephritis

50

Goodpasture's syndrome

51

Grave's disease

52

Guillain-Barre syndrome

53

Hashimoto's thyroiditis

54

Hemolytic anemia

55

Herpes gestationis or pemphigoid gestationis (PG)

56

Hiradenitis Suppurativa (HS) (Acne inversa)

57

Hypogammalglobulinemia

58

IgA Nephropathy

59

IgG4-related sclerosing disease

60

Immune thrombocytopic purpura (ITP)

61

Inclusion body myositis (IBM)

62

Interstitial cystitis

63

Kawasaki disease

64

Lambert-eaton syndrome

65

Leukocytoclastic vasculitis

66

Lichen planus

67

Ligenous conjuctivitis

68

Linear IgA disease (LAD)

69

Lupus

70

Lyme disease chronic

71

Meniere's disease

72

Mixed connective tissure disease

73

Mooren's ulcer

74

Mucha-Habermann disease

75

Multifocal motor neuropathy

76

Multiple sclerosis

77

Myasthenia gravis

78

Myositis
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S.No.

Autoimmune disease

79

Narcolepsy

80

Neuromyelitis optica

81

Neutropenia

82

Ocular cicatricial pemphigoid

83

Optic neuritis

84

Palindromic rheumatism

85

Paraneoplastic cerebellar degeneration

86

Paroxysmal noctural hemoglobinuria

87

Parry Romberg syndrome

88

Pars planitis (peripheral uveitis)

89

Parsonage-Turner syndrome

90

Pemphigus

91

Peripheral neuropathy

92

Perivenous encephalomyelitis

93

95

Pernicious anemia
Polyneuropathy, organomegaly, endocrinopathy, monoclonal
gammopathy, skin changes (POEMS syndrome)
Polyglandular syndromes type I, II, III

96

Polymyositis

97

Postmyocardial infarction syndrome

98

Postpericardiotomy syndrome

99

Primary biliary cirrhosis

100

Primary sclerosing cholangitis

101

Progesterone dermatitis

102

Psoriasis

103

Psoriatic arthritis

104

Pure red cell aplasia

105

Pyoderma gangrenosum

106

Raynaud's phenomenon

107

Reactive arthritis

108

Reflex sympathetic dystrophy

109

Relapsing polychondritis

110

Restless legs syndrome

111

Retroperitoneal fibrosis

112

Rheumatic fever

113

Rheumatic arthritis

114

Sarcoidosis

115

Schmidt syndrome

116

Scleritis

117

Sjogren's syndrome

118

Stiff person syndrome
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S.No.

Autoimmune disease

119

Subacute bacterial endocarditis

120

Susac's syndrome

121

Sympathetic ophthalmia

122

Takayasu's arteritis

123

Thrombocytopenic purpura

124

Tolosa-Hunt syndrome

125

Transverse myelitis

126

Ulcerative colitis

127

Undifferentiated connective tissue disease

128

Uveitis, Panuveitis

129

Vasculitis

130

Vitiligo

131

Vogt-Koyanagi-Harada disease
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Appendix 7.2: Codes for identification of chemotherapy and radiation for the treatment of late-stage melanoma
Chemotherapy

HCPCS Codes

CPT Codes

Amifostine

'J0207'

'96374'

Bacillus Calmette-Guérin

'90585', '90586', 'J9031'

'90471', '90472'

Bleomycin

'J9040'

'96401', '96409'

Carboplatin

'J9045'

'96409', '96413'⁑, '96415'⁑

Cisplatin

'J9060'

'96409', '96413',⁑ '96415'⁑

Carmustine

'J9050'

'96413', '96415'⁑

Dacarbazine

'J9130'

'96409', ' 96413'⁑

Docetaxel

'J9171 '

'96413⁑'

Granulocyte-macrophage colony-stimulating

'J2820'

'96365', '96366', '96372'

IL-2- aldesleukin

'J9015'

'96409'

Interferon alfa-2b

'C9399',* 'J9999'*

'96372', '96401'

Lomustine

'J8999'*, 'S0178'

-

Megestrol acetate

'J8999'*, 'S0179'

-

Melphalan

'J9245'

'96409', '96413'⁑

Nab-paclitaxel

'J9264'

-

Paclitaxel

'J9265'

'96413'⁑, '96415'⁑

Temozolomide

'J8700'

-

Vincristine

'J9370'

'96409'

Vinblastine

'J9360'

'96409'

Radiation

HCPCS Codes

CPT Codes

Intensity Modulated Radiation Therapy

-

'77301', '77338'

Stereotactic Body Radiation Therapy

'G0339', 'G0340'

'77373', '77435'

factor

2D and 3D Conformal

Stereotactic Radiosurgery

'G6003', 'G6004', 'G6005', 'G6006', 'G6007',
'G6008', 'G6009', 'G6010', 'G6011', 'G6012', 'G6013',
'G6014'
'G0339', 'G0340'

Brachytherapy

'77280', '77285', '77290',
'77295', '77402', '77407', '77412'
'77371', '77372', '77432'

'67218', '77316', '77317',
'77318', '77778'
* Unclassified drugs/biologics; Not otherwise classified, antineoplastics; ⁑ Not included for identification of chemotherap

91

Appendix 7.3
Percent with Immune Checkpoint Inhibitor (ICI) use by Selected Patient-level Characteristics
among Older Adults (age >65 years) with Incident Late-stage Melanoma during 2012 and 2015
Linked Surveillance, Epidemiology, and End Results and Medicare Claims Database
ALL
ICI
No ICI
Characteristics
p-value
Significance
%
%
%
ALL

100

5.6

94.4

2012

24.2

3.2

96.8

2013

24.1

5.8

94.2

2014

25.8

6.4

93.6

2015

25.9

6.8

93.2

Yes

84.8

5.5

94.5

No

15.2

6.0

94.0

65 to 69

20.2

6.8

93.2

70 to 74

22.2

7.6

92.4

75 to 79

20

5.0

95.0

80 and older

37.5

4.1

95.9

Females

35.8

4.5

95.5

Males

64.2

6.2

93.8

Whites

96.1

5.5

94.5

Non-Whites

3.9

7.3

92.7

Unmarried

50.9

7.3

92.7

Married

49.1

3.9

96.1

Yes

3.8

10.0

90.0

No

96.2

5.4

94.6

Yes

20.0

12.5

87.5

No

80.0

3.8

96.2

62.0

6.2

93.8

Year of diagnosis
0.0008

***

Multimorbidity
0.62

Age (in years)
0.0004

***

0.014

*

Sex

Race
0.29

Marital status
<0.0001

***

0.0104

*

<0.0001

***

<0.0001

***

Dual Medicare/Medicaid eligibility

Oncologist visits

Primary care physicians
Yes

No
38.0
4.6
95.4
Note: Based on 4,519 older adults with incident late-stage (Stage III/IV) melanoma continuously enrolled in
Medicare Part A & B fee-for service programs 12 months prior to incident cancer diagnosis.
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Appendix 7.4: Parameter estimates of select variables of GLMM on average outpatient expenditures
No Interaction
With interaction
Variables
Unadjusted analysis
Beta
SE
Prob
Beta
SE
Prob
Time
0.40
0.04
<0.001
0.41
0.04
<0.001
ICI use
N/A
Yes
1.66
0.05
<0.001
No
(ref)
Multimorbidity
N/A
Yes
0.93
0.07
<0.001
No
(ref)
ICI-Multimorbidity Interaction
N/A
Yes ICI and Yes Multimorbidity
0.25
0.09
0.005
Yes ICI and No Multimorbidity
(ref)
No ICI and Yes Multimorbidity
-1.26
0.08
<0.001
No ICI and No Multimorbidity
-2.24
0.11
<0.001
Time squared
-0.07
0.01
<0.001
-0.07
0.01
<0.001
No Interaction

Time
ICI use
Yes
No
Multimorbidity
Yes
No
ICI-Multimorbidity Interaction
Yes ICI and Yes Multimorbidity
Yes ICI and No Multimorbidity
No ICI and Yes Multimorbidity
No ICI and No Multimorbidity
Time squared

Beta
0.17

SE
0.03

1.18
(ref)

0.07

0.77
(ref)
N/A

0.07

With interaction

Fully adjusted analysis╪
Prob
Beta
<0.001
0.18
N/A
<0.001

SE
0.03

Prob
<0.001

0.17

0.77

0.16
0.17
0.01

<0.001
<0.001
<0.001

N/A

-0.06

0.01

<0.001

<0.001

0.05
(ref)
-0.97
-1.79
-0.06

Note: Based on 6 repeated observations of 4,519 older adults with incident late-stage (Stage III/IV)
melanoma continuously enrolled in Medicare Parts A and B fee-for-service programs 12 months prior to
incident cancer diagnosis.
╪
Fully adjusted model also included year of diagnosis, age, sex, race, marital status, dual eligibility,
oncologist visit, and primary care physician visits.
Probability p<0.05 was considered significant
Abbreviations: GLMM, Generalized linear mixed model; ICI, Immune checkpoint inhibitors; N/A, Not
applicable; Prob, Probability; ref, Reference; SE, Standard error
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Appendix 7.5: Parameter estimates of select variables of GLMM on average home healthcare expenditures
No Interaction
Variables
Time
ICI use
Yes
No
Multimorbidity
Yes
No
ICI-Multimorbidity Interaction
Yes ICI and Yes Multimorbidity
Yes ICI and No Multimorbidity
No ICI and Yes Multimorbidity
No ICI and No Multimorbidity
Time squared

Time
ICI use
Yes
No
Multimorbidity
Yes
No
ICI-Multimorbidity Interaction
Yes ICI and Yes Multimorbidity
Yes ICI and No Multimorbidity
No ICI and Yes Multimorbidity
No ICI and No Multimorbidity
Time squared

With interaction
Unadjusted analysis

Beta
0.33

SE
0.06

Prob
<0.001

0.23
(ref)

0.13

0.820

Beta
0.33
N/A

SE
0.06

Prob
<0.001

0.31

0.009

0.30
0.34
0.01

0.008
0.006
<0.001

SE
0.07

Prob
0.002

0.62

0.928

0.61
0.63
0.01

0.696
0.092
<0.001

N/A
1.64
(ref)
N/A

-0.05

0.16

0.01

Beta
0.19

SE
0.06

0.12
(ref)

0.25

<0.001

<0.001

0.81
(ref)
0.79
-0.93
-0.06

Fully adjusted analysis╪
Prob
Beta
0.002
0.20
N/A
0.622
N/A

1.21
(ref)
N/A

-0.05

0.19

0.01

<0.001

<0.001

0.06
(ref)
0.24
-1.07
-0.05

Note: Based on 6 repeated observations of 4,519 older adults with incident late-stage (Stage III/IV)
melanoma continuously enrolled in Medicare Parts A and B fee-for-service programs 12 months prior to
incident cancer diagnosis.
╪
Fully adjusted model also included year of diagnosis, age, sex, race, marital status, dual eligibility,
oncologist visit, and primary care physician visits.
Probability p<0.05 was considered significant
Abbreviations: GLMM, Generalized linear mixed model; ICI, Immune checkpoint inhibitors; N/A, Not
applicable; Prob, Probability; ref, Reference; SE, Standard error
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Appendix 7.6: Parameter estimates of select variables of GLMM on average inpatient expenditures
No Interaction
With interaction
Variables
Unadjusted analysis
Beta
SE
Prob
Beta
SE
Prob
Time
1.94
0.17
<0.001
1.93
0.17
<0.001
ICI use
N/A
Yes
0.68
0.17
<0.001
No
(ref)
Multimorbidity
N/A
Yes
1.05
0.15
<0.001
No
(ref)
ICI-Multimorbidity Interaction
N/A
Yes ICI and Yes Multimorbidity
0.20
0.34
0.551
Yes ICI and No Multimorbidity
(ref)
No ICI and Yes Multimorbidity
-0.27
0.29
0.342
No ICI and No Multimorbidity
-1.40
0.32
<0.001
Time squared
-0.34
0.03
<0.001
-0.33
0.03
<0.001
No Interaction
With interaction

Time
ICI use
Yes
No
Multimorbidity
Yes
No
ICI-Multimorbidity Interaction
Yes ICI and Yes Multimorbidity
Yes ICI and No Multimorbidity
No ICI and Yes Multimorbidity
No ICI and No Multimorbidity
Time squared

Beta
1.56

SE
0.22

-0.07
(ref)

0.16

Fully adjusted analysis╪
Prob
Beta
<0.001
1.56
N/A
0.676

SE
0.22

Prob
<0.001

0.31

0.961

0.29
0.35
0.04

0.463
0.179
<0.001

N/A
0.63
(ref)
N/A

-0.30

0.25

0.04

0.011

<0.001

0.02
(ref)
0.21
-0.46
-0.30

Note: Based on 6 repeated observation of 4,519 older adults with incident late-stage (Stage III/IV)
melanoma continuously enrolled in Medicare Parts A and B fee-for-service programs 12 months prior to
incident cancer diagnosis.
╪
Fully adjusted model also included year of diagnosis, age, sex, race, marital status, dual eligibility,
oncologist visit, and primary care physician visits.
Probability p<0.05 was considered significant
Abbreviations: GLMM, Generalized linear mixed model; ICI, Immune checkpoint inhibitors; N/A, Not
applicable; Prob, Probability; ref, Reference; SE, Standard error
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